[go: up one dir, main page]

EP2650284A1 - Dérivés hétérocycliques comme modulateurs de récepteurs du glutamate métabotropique - Google Patents

Dérivés hétérocycliques comme modulateurs de récepteurs du glutamate métabotropique Download PDF

Info

Publication number
EP2650284A1
EP2650284A1 EP12163604.7A EP12163604A EP2650284A1 EP 2650284 A1 EP2650284 A1 EP 2650284A1 EP 12163604 A EP12163604 A EP 12163604A EP 2650284 A1 EP2650284 A1 EP 2650284A1
Authority
EP
European Patent Office
Prior art keywords
alkyl
phenylethynyl
rac
dihydro
ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP12163604.7A
Other languages
German (de)
English (en)
Inventor
designation of the inventor has not yet been filed The
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merz Pharma GmbH and Co KGaA
Original Assignee
Merz Pharma GmbH and Co KGaA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merz Pharma GmbH and Co KGaA filed Critical Merz Pharma GmbH and Co KGaA
Priority to EP12163604.7A priority Critical patent/EP2650284A1/fr
Publication of EP2650284A1 publication Critical patent/EP2650284A1/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D497/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D497/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Definitions

  • the present invention relates to heterocyclic derivatives, which may act as novel metabotropic glutamate receptor (mGluR) modulators, methods for their synthesis and the treatment and/or prevention of various diseases and disorders, including neurological disorders, by administration of such derivatives.
  • mGluR metabotropic glutamate receptor
  • Neuronal stimuli are transmitted by the central nervous system (CNS) through the interaction of a neurotransmitter released by a neuron, which neurotransmitter has a specific effect on a neuroreceptor of another neuron.
  • L-Glutamic acid is considered to be a major excitatory neurotransmitter in the mammalian CNS, consequently playing a critical role in a large number of physiological processes.
  • Glutamate-dependent stimulus receptors are divided into two main groups. The first group comprises ligand-controlled ion channels whereas the other comprises metabotropic glutamate receptors (mGluR). Metabotropic glutamate receptors are a subfamily of G-protein-coupled receptors (GPCR). There is increasing evidence for a peripheral role of both ionotropic and metabotropic glutamate receptors outside the CNS e.g, in chronic pain states.
  • MGluR1 and mGluR5 belong to Group I which are positively coupled to phospholipase C and their activation leads to a mobilization of intracellular calcium ions.
  • MGluR2 and mGluR3 belong to Group II and mGluR4, mGluR6, mGluR7 and mGluR8 belong to Group III, both of which are negatively coupled to adenylyl cyclase, i.e., their activation causes a reduction in second messenger cAMP and thus a dampening of neuronal activity.
  • the orthosteric ligand e.g. glutamate
  • the venus fly trap module Bockaert, et al., The EMBO Journal, 1999, 18, 1723-1729 .
  • MPEP a binding site for allosteric ligands
  • the mGluR5 modulators have been shown to modulate the effects of the presynaptically released neurotransmitter glutamate via postsynaptic mechanisms (receptors). Moreover, as these modulators may be both positive and/or negative mGluR5 modulators, such modulators may increase or inhibit the effects mediated through these metabotropic glutamate receptors.
  • Modulators which are negative mGluR5 modulators decrease the effects mediated through metabotropic glutamate receptors. Since a variety of patho-physiological processes and disease states affecting the CNS are thought to be related to abnormal glutamate neurotransmission, and mGluR5 receptors are shown to be expressed in many areas of the CNS and in PNS (peripheral nervous system), modulators of these receptors could be therapeutically beneficial in the treatment of diseases involving CNS and PNS.
  • mGluR5 positive or negative modulators may be administered to provide neuroprotection and/or disease modification in the following acute or chronic pathological conditions or to provide a symptomatological effect on the following conditions: Alzheimer's disease, Creutzfeld-Jakob's syndrome/disease, bovine spongiform encephalopathy (BSE), prion related infections, diseases involving mitochondrial dysfunction, diseases involving ⁇ -amyloid and/or tauopathy, Down's syndrome, hepatic encephalopathy, Huntington's disease, motor neuron diseases, amyotrophic lateral sclerosis (ALS), multiple system atrophy, olivoponto-cerebellar atrophy, synucleinopathies, alpha-synucleinopathies, Lewy body dementia, neurodegeneration with Brain Iron Accumulation, Parkinson-plus syndrome, Pick's disease, progressive supranuclear palsy (PSP), frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17), neurodegenerative diseases,
  • mGluR5 negative or positive modulators may also be administered to provide inhibition of tumour cell growth, migration, invasion, adhesion and toxicity in the peripheral tissues, peripheral nervous system and CNS.
  • mGluR5 modulators may be administered to provide therapeutic intervention in neoplasia, hyperplasia, dysplasia, cancer, carcinoma, sarcoma, oral cancer, squamous cell carcinoma (SCC), oral squamous cell carcinoma (SCC), lung cancer, lung adenocarcinoma, breast cancer, prostate cancer, gastric cancer, liver cancer, colon cancer, colorectal carcinoma, rhabdomyosarcoma, brain tumour, tumour of a nerve tissue, glioma, malignant glioma, astroglioma, neuroglioma, neuroblastoma, glioblastoma, medulloblastoma, cancer of skin cells, melanoma, malignant melanoma, epithelial neoplasm, lymphom
  • mGluR5 positive or negative modulators may also be administered to provide disease modification and/or to provide a symptomatological effect on the following conditions: diabetes, hyperammonemia and liver failure.
  • mGluR5 negative or positive modulators include those indications wherein a particular condition does not necessarily exist but wherein a particular physiological parameter may be improved through administration of the instant compounds, for example cognitive enhancement, learning impairment and/or neuroprotection.
  • Positive modulators may be particularly useful in the treatment of positive and negative symptoms and cognitive deficits in schizophrenia as well as cognitive deficits in various forms of dementia and mild cognitive impairment.
  • Silent modulators may be useful for attenuation of disease states emerging from disregulation of a natural ligand for the allosteric site.
  • mGluR modulators may have activity when administered in combination with other substances exhibiting neurological effects via different mechanisms.
  • Simultaneous administration of Group I mGluR modulators and compounds such as L-DOPA, dopaminomimetics, and/or neuroleptics may be useful in treating various conditions including drug induced dyskinesias, neuroleptic-induced dyskinesias, haloperidol-induced dyskinesias, dopaminomimetic-induced dyskinesias.
  • heterocyclic derivatives are potent mGluR5 modulators. Therefore, these substances may be therapeutically beneficial in the treatment of conditions which involve abnormal glutamate neurotransmission or in which modulation of mGluR5 receptors results in therapeutic benefit.
  • These substances may be administered in the form of a pharmaceutical composition, wherein they are present together with one or more pharmaceutically acceptable diluents, carriers, or excipients.
  • An additional object of the invention is the provision of processes for producing the heterocyclic derivatives.
  • a further aspect of the invention relates to a compound of Formula I, wherein R 1 represents aryl or heteroaryl.
  • Such a compound of Formula I wherein R 2 represents H, OH, C 1-6 alkyl, or C 1-6 alkoxy and R 3 represents H or C 1-6 alkyl or R 2 and R 3 together with the carbon atom to which they are attached form a 5-membered ring containing one or two heteroatoms selected from sulfur, oxygen, and nitrogen, wherein the ring may be optionally substituted by one or more substituents selected from C 1-6 alkyl, oxo, phenyl, and cycloC 3-7 alkyl.
  • Such a compound of Formula I wherein R 2 represents H, OH, methyl, or methoxy and R 3 represents H or methyl or R 2 and R 3 together with the carbon atom to which they are attached form an oxazolidine ring substituted by an oxo group and a methyl, propyl, phenyl or cyclopropyl group.
  • Such a compound of Formula I wherein X represents NR 10 and R 10 represents C 1-6 alkylcarbonyl, cycloC 3-12 alkylcarbonyl, C 1-6 alkoxycarbonyl, aryloxycarbonyl, di-(C 1-6 alkyl)aminocarbonyl (wherein the alkyl moieties may be optionally substituted by one or more halogen atoms), -C(O)-C(O)-C 1-6 alkoxy, C 1-6 alkylsulfinyl, C 1-6 alkylsulfonyl, cycloC 3-7 alkylsulfonyl, arylsulfonyl, heterocyclylsulfonyl, or di-(C 1-6 alkyl)aminosulfonyl.
  • Such a compound of Formula I wherein X represents NR 10 and R 4 and R 10 together with the atoms to which they are attached form a 6-membered ring optionally containing one or two additional heteroatoms selected from sulfur, oxygen, and nitrogen, wherein the ring may be optionally substituted by one or more substituents selected from oxo and C 1-6 alkyl.
  • Such a compound of Formula I wherein R 4 and R 10 together with the atoms to which they are attached form a tetrahydropyrimidine ring optionally substituted by one or more substituents selected from oxo and C 1-6 alkyl.
  • Such a compound of Formula I wherein X represents CR 8 R 9 and R 2 and R 8 together with the carbon atoms to which they are attached form a 5 or 6 membered ring optionally containing one or two heteroatoms selected from sulfur, oxygen, and nitrogen, wherein the ring may be optionally substituted by one or more substituents selected from C 1-6 alkyl, trifluoroethyl, trifluoropropyl, C 1-6 alkoxycarbonyl, and di-(C 1-6 alkyl)aminocarbonyl or R 2 and R 8 together with the carbon atoms to which they are attached form a 5-membered heteroaromatic ring optionally substituted by one or more C 1-6 alkyl groups.
  • Such a compound of Formula I wherein X represents CR 8 R 9 and R 2 and R 8 together with the carbon atoms to which they are attached form an oxazine ring optionally substituted by one or more substituents selected from C 1-6 alkyl, trifluoroethyl, trifluoropropyl, C 1-6 alkoxycarbonyl, and di-(C 1-6 alkyl)aminocarbonyl; R 2 and R 8 together with the carbon atoms to which they are attached form a pyrrolidine ring optionally substituted by one or more C 1-6 alkoxycarbonyl groups; or R 2 and R 8 together with the carbon atoms to which they are attached form a pyrazole ring optionally substituted by one or more C 1-6 alkyl groups.
  • Such a compound of Formula I wherein X represents CR 8 R 9 and R 4 and R 8 together with the carbon atoms to which they are attached form a 5 membered ring optionally containing one or two heteroatoms selected from sulfur, oxygen, and nitrogen, wherein the ring may be optionally substituted by one or more C 1-6 alkoxycarbonyl groups.
  • Such a compound of Formula I wherein Y represents -CR 11 R 12 , O, NR 17 , or a bond.
  • Such a compound of Formula I wherein Y represents NR 17 and R 17 represents C 1-6 alkyl; or Y represents -CR 11 R 12 and R 11 and R 12 each represent H or R 4 and R 11 together with the carbon atoms to which they are attached form a 5 or 6 membered ring optionally containing one or two heteroatoms selected from sulfur, oxygen, and nitrogen, wherein the ring may be optionally substituted by one or more C 1-6 alkoxycarbonyl groups.
  • Such a compound of Formula I wherein R 4 and R 11 together with the carbon atoms to which they are attached form a pyrrolidine ring optionally substituted by C 1-6 alkoxycarbonyl, a cyclopentane ring, or a cyclohexane ring.
  • R 1 represents phenyl optionally substituted by one or more substituents selected from F, C 1-6 alkyl, and cyano; pyridyl optionally substituted by one or more amino groups; or imidazopyridyl.
  • a further aspect of the invention relates to a compound of Formula I , which is selected from those of Formula IA wherein R 1 -R 5 , R 8 -R 9 , and Y are as defined above for Formula I, and optical isomers, prodrugs, pharmaceutically acceptable salts, hydrates, solvates, and polymorphs thereof.
  • a further aspect of the invention relates to a compound of Formula IA , wherein R 1 represents aryl or heteroaryl.
  • a further aspect of the invention relates to a compound of Formula IA , wherein R 1 represents aryl or heteroaryl; R 3 -R 5 and R 9 each represent hydrogen; Y represents CH 2 ; and R 2 and R 8 together with the carbon atoms to which they are attached form a 5 or 6 membered ring optionally containing one or two heteroatoms selected from sulfur, oxygen, and nitrogen, wherein the ring may be optionally substituted by one or more substituents selected from C 1-6 alkyl, trifluoroethyl, trifluoropropyl, C 1-6 alkoxycarbonyl, and di-(C 1-6 alkyl)aminocarbonyl.
  • Such a compound of Formula IA wherein R 2 and R 8 together with the carbon atoms to which they are attached form an oxazine ring optionally substituted by one or more substituents selected from C 1-6 alkyl, trifluoroethyl, trifluoropropyl, C 1-6 alkoxycarbonyl, and di-(C 1-6 alkyl)aminocarbonyl; or R 2 and R 8 together with the carbon atoms to which they are attached form a pyrrolidine ring optionally substituted by one or more C 1-6 alkoxycarbonyl groups.
  • Such a compound of Formula IA wherein wherein R 2 and R 8 together with the carbon atoms to which they are attached form an oxazine ring substituted by one or more C 1-6 alkyl (e.g., methyl, ethyl, propyl, isopropyl) groups.
  • C 1-6 alkyl e.g., methyl, ethyl, propyl, isopropyl
  • Such a compound of Formula IA wherein R 2 and R 8 together with the carbon atoms to which they are attached form an oxazine ring substituted by one or more trifluoroethyl groups.
  • Such a compound of Formula IA wherein R 2 and R 8 together with the carbon atoms to which they are attached form an oxazine ring substituted by one or more trifluoropropyl groups.
  • Such a compound of Formula IA wherein R 2 and R 8 together with the carbon atoms to which they are attached form an oxazine ring substituted by one or more C 1-6 alkoxycarbonyl (e.g., methoxycarbonyl) groups.
  • C 1-6 alkoxycarbonyl e.g., methoxycarbonyl
  • Such a compound of Formula IA wherein R 2 and R 8 together with the carbon atoms to which they are attached form an oxazine ring substituted by one or more di-(C 1-6 alkyl)aminocarbonyl (e.g., dimethylaminocarbonyl) groups.
  • Such a compound of Formula IA wherein R 2 and R 8 together with the carbon atoms to which they are attached form a pyrrolidine ring substituted by one or more C 1-6 alkoxycarbonyl (e.g., methoxycarbonyl) groups.
  • R 1 represents phenyl optionally substituted by one or more substituents selected from F, C 1-6 alkyl, and cyano; pyridyl optionally substituted by one or more amino groups; or imidazopyridyl.
  • Such a compound of Formula IA wherein R 1 represents pyridyl substituted by one or more amino groups.
  • a further aspect of the invention relates to a compound of Formula IA, wherein R 1 represents aryl or heteroaryl; R 2 , R 3 , R 5 and R 9 each represent hydrogen; Y represents a bond; and R 4 and R 8 together with the carbon atoms to which they are attached form a 5 membered ring optionally containing one or two heteroatoms selected from sulfur, oxygen, and nitrogen, wherein the ring may be optionally substituted by one or more C 1-6 alkoxycarbonyl groups.
  • Such a compound of Formula IA wherein R 4 and R 8 together with the carbon atoms to which they are attached form a pyrrolidine ring optionally substituted by one or more C 1-6 alkoxycarbonyl (e.g., methoxycarbonyl) groups.
  • C 1-6 alkoxycarbonyl e.g., methoxycarbonyl
  • R 1 represents phenyl optionally substituted by one or more substituents selected from F, C 1-6 alkyl, and cyano; pyridyl optionally substituted by one or more amino groups; or imidazopyridyl.
  • a further aspect of the invention relates to a compound of Formula I, which is selected from those of Formula IB wherein R 1 -R 5 , R 11 -R 12 , and X are as defined above for Formula I , and optical isomers, prodrugs, pharmaceutically acceptable salts, hydrates, solvates, and polymorphs thereof.
  • a further aspect of the invention relates to a compound of Formula IB, wherein R 1 represents aryl or heteroaryl.
  • a further aspect of the invention relates to a compound of Formula IB, wherein X represents CR 8 R 9 or NR 10 , wherein R 8 -R 10 are as defined above for Formula I, and R 4 and R 11 together with the carbon atoms to which they are attached form a 5 or 6 membered ring optionally containing one or two heteroatoms selected from sulfur, oxygen, and nitrogen, wherein the ring may be optionally substituted by one or more C 1-6 alkoxycarbonyl groups.
  • Such a compound of Formula IB wherein X represents CR 8 R 9 , wherein R 8 and R 9 each represent H or X represents NR 10 wherein R 10 represents C 1-6 alkoxycarbonyl (e.g., methoxycarbonyl).
  • Such a compound of Formula IB wherein R 4 and R 11 together with the carbon atoms to which they are attached form a pyrrolidine ring optionally substituted by one or more C 1-6 alkoxycarbonyl (e.g., methoxycarbonyl) groups, a cyclopentane ring, or a cyclohexane ring.
  • C 1-6 alkoxycarbonyl e.g., methoxycarbonyl
  • R 1 represents phenyl optionally substituted by one or more substituents selected from F, C 1-6 alkyl, and cyano; pyridyl optionally substituted by one or more amino groups; or imidazopyridyl.
  • a further aspect of the invention relates to a compound of Formula I, which is selected from those of Formula IC wherein R 1 -R 5 and R 10 -R 12 are as defined above for Formula I, and optical isomers, prodrugs, pharmaceutically acceptable salts, hydrates, solvates, and polymorphs thereof.
  • a further aspect of the invention relates to a compound of Formula IC, wherein R 1 represents aryl or heteroaryl.
  • a further aspect of the invention relates to a compound of Formula IC, wherein R 1 represents aryl or heteroaryl and R 10 represents C 1-6 alkylcarbonyl, cycloC 3-12 alkylcarbonyl, C 1-6 alkoxycarbonyl, aryloxycarbonyl, di-(C 1-6 alkyl)aminocarbonyl (wherein the alkyl moieties may be optionally substituted by one or more halogen atoms), -C(O)-C(O)-C 1-6 alkoxy, C 1-6 alkylsulfinyl, C 1-6 alkylsulfonyl, cycloC 3-7 alkylsulfonyl, arylsulfonyl, heterocyclylsulfonyl, or di-(C 1-6 alkyl)aminosulfonyl.
  • a further aspect of the invention relates to a compound of Formula IC , wherein R 1 represents aryl or heteroaryl and R 4 and R 10 together with the atoms to which they are attached form a 6-membered ring optionally containing one or two additional heteroatoms selected from sulfur, oxygen, and nitrogen, wherein the ring may be optionally substituted by one or more substituents selected from oxo and C 1-6 alkyl.
  • Such a compound of Formula IC wherein R 4 and R 10 together with the atoms to which they are attached form a tetrahydropyrimidine ring optionally substituted by one or more substituents selected from oxo and C 1-6 alkyl (e.g., methyl).
  • Such a compound of Formula IC wherein R 4 and R 10 together with the atoms to which they are attached form a tetrahydropyrimidine ring substituted by two or more substituents selected from oxo and C 1-6 alkyl (e.g., methyl).
  • R 1 represents phenyl optionally substituted by one or more substituents selected from F, C 1-6 alkyl, and cyano; pyridyl optionally substituted by one or more amino groups; or imidazopyridyl.
  • Such a compound of Formula IC wherein R 1 represents phenyl substituted by one or more fluorine atoms.
  • Such a compound of Formula IC wherein R 1 represents phenyl substituted by one or more C 1-6 alkyl (e.g., methyl) groups.
  • Such a compound of Formula IC wherein R 1 represents phenyl substituted by one or more cyano groups.
  • Such a compound of Formula IC wherein R 1 represents pyridyl substituted by one or more amino groups.
  • a further aspect of the invention relates to a compound of Formula I, which is selected from those of Formula ID , wherein R 2 , R 4 -R 5 , R 8 , and Y are as defined above for Formula I , and optical isomers, prodrugs, pharmaceutically acceptable salts, hydrates, solvates, and polymorphs thereof.
  • a further aspect of the invention relates to a compound of Formula ID , wherein R 1 represents aryl or heteroaryl.
  • a further aspect of the invention relates to a compound of Formula ID, wherein R 2 and R 8 together with the carbon atoms to which they are attached form a 5-membered heteroaromatic ring optionally substituted by C 1-6 alkyl.
  • Such a compound of Formula ID wherein R 2 and R 8 together with the carbon atoms to which they are attached form a pyrazole ring optionally substituted by one or more C 1-6 alkyl (e.g., methyl) groups.
  • R 1 represents phenyl optionally substituted by one or more substituents selected from F, C 1-6 alkyl, and cyano; pyridyl optionally substituted by one or more amino groups; or imidazopyridyl.
  • the invention relates to a compound of Formula I as defined above or an optical isomer, pharmaceutically acceptable salt, hydrate, solvate or polymorph thereof for use in therapy.
  • the invention relates to a compound of Formula I as defined above or an optical isomer, pharmaceutically acceptable salt, hydrate, solvate or polymorph thereof for the treatment and/or prevention of a condition or disease associated with abnormal glutamate neurotransmission, including a condition or disease which is affected or facilitated by modulation of the mGluR5 receptor, including for the conditions or diseases selected from those described earlier in the description.
  • the invention relates to a compound of Formula I as defined above or an optical isomer, pharmaceutically acceptable salt, hydrate, solvate or polymorph thereof for the treatment and/or prevention of a CNS disorder.
  • the invention relates to a compound of Formula I as defined above or an optical isomer, pharmaceutically acceptable salt, hydrate, solvate or polymorph thereof for the treatment and/or prevention of abnormal glutamate neurotransmission.
  • the invention additionally relates to a compound of Formula I as defined above or an optical isomer, pharmaceutically acceptable salt, hydrate, solvate or polymorph thereof for modulation of the mGluR5 receptor.
  • the invention furthermore relates to such a compound for treatment, prevention and or modulation of a condition or disease selected from those described earlier in the description.
  • the invention still further relates to such a compound for treatment, prevention and or modulation of a a physiological parameter, such as cognitive disorder, whether or not a specific identifiable condition exists.
  • a further aspect of the invention relates to a compound of Formula I as defined above or an optical isomer, pharmaceutically acceptable salt, hydrate, solvate or polymorph thereof for the treatment and/or prevention of a condition associated with abnormal glutamate neurotransmission or in which modulation of mGluR5 receptors results in therapeutic benefit.
  • the conditions which may be treated have already been described above. Such conditions and indications include:
  • a further aspect of the invention relates to a compound of Formula I as defined above or an optical isomer, pharmaceutically acceptable salt, hydrate, solvate or polymorph thereof for the treatment of binge eating disorders.
  • the invention relates to the use of a compound of Formula I as defined above or an optical isomer, pharmaceutically acceptable salt, hydrate, solvate or polymorph thereof for the preparation of a medicament for treating or preventing a condition or disease associated with abnormal glutamate neurotransmission.
  • a use includes the use of such a compound for the preparation of a medicament for the prevention and/or treatment of a condition or disease in an animal including a human being which condition or disease is affected or facilitated by modulation of the mGluR5 receptor.
  • the invention relates to a method for treating or preventing a condition associated or disease associated with abnormal glutamate neurotransmission, including a condition or disease which is affected or facilitated by modulation of the mGluR5 receptor, including for the conditions or diseases selected from those described earlier in the description.
  • a further aspect of the invention relates to the use of isotopic derivatives of the compounds of Formula I as PET ligands.
  • the invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising as active ingredient at least one compound of Formula I as defined above or an optical isomer, pharmaceuctically acceptable salt, hydrate, solvate or polymorph thereof, together with one or more pharmaceutically acceptable excipients.
  • the mGluR modulators as described above are expected to have a high activity when administered in combination with other substances exhibiting neurological effects via different mechanisms.
  • the invention thus relates to a compound of Formula I as defined above or an optical isomer, pharmaceutically acceptable salt, hydrate, solvate or polymorph thereof for neuroprotection and/or for cognitive enhancement in combination with at least one NMDA receptor antagonist such as Memantine.
  • a further aspect of the invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising at least two different active ingredients, selected from least one compound of Formula I as defined above, and, additionally, at least one NMDA-antagonist, together with one or more pharmaceutically acceptable excipients.
  • These compositions may be used for the treatment of CNS-related diseases, cognitive enhancement and for neuro-protection.
  • the invention thus additionally provides a composition comprising at least two different active ingredients, selected from least one compound of Formula I as defined above, and, additionally, at least one NMDA-antagonist for the treatment of any of the conditions indicated herein, including CNS-related diseases, cognitive enhancement and for neuro-protection.
  • This invention also relates to a pharmaceutical composition
  • a pharmaceutical composition comprising a combination of a compound of Formula I as described above and an NMDA receptor antagonist, including compositions wherein the NMDA receptor antagonist is e.g. Memantine and pharmaceutically acceptable salts, polymorphs, hydrates and solvates thereof.
  • the NMDA receptor antagonist is e.g. Memantine and pharmaceutically acceptable salts, polymorphs, hydrates and solvates thereof.
  • the invention also relates to a pharmaceutical composition
  • a pharmaceutical composition comprising at least two different active ingredients, selected from at least one compound of Formula I as defined above, and, additionally, at least one active ingredient selected from L-DOPA, other dopaminomimetics (such as antiparkinsonian dopaminomimetics, including bromocriptine, cabergolin, ropinirole, pramiperole, pergolide, rotigotine), and neuroleptics (such as classical neuroleptics, including haloperidol, perphenazin, chlorpromazine, metoclopramide or atypicals such as clozapine, risperidone or olanzapine).
  • dopaminomimetics such as antiparkinsonian dopaminomimetics, including bromocriptine, cabergolin, ropinirole, pramiperole, pergolide, rotigotine
  • neuroleptics such as classical neuroleptics, including haloperidol, perphenazin
  • the invention also relates to a method of providing neuroprotection in a living animal, including a human, comprising the step of administering to a living animal, including a human, a therapeutically effective amount of a composition as described above.
  • the invention relates to the use of a composition as described above for the manufacture of a medicament to provide neuroprotection in an animal, including a human.
  • the invention also relates to a process for the synthesis or preparation of a compound of Formula I or an optical isomer, prodrug, pharmaceutically acceptable salt, hydrate, solvate, or polymorph thereof, wherein a compound of Formula II is treated with a substituted acetylene of Formula III in the presence of a suitable catalyst, such as Pd[PPh 3 ] 2 Cl 2 , to yield a compound of Formula I , which may be converted to a prodrug, pharmaceutically acceptable salt, hydrate, solvate, or polymorph.
  • a suitable catalyst such as Pd[PPh 3 ] 2 Cl 2
  • the invention also relates to a process for the synthesis or preparation of a compound of Formula I or an optical isomer, prodrug, pharmaceutically acceptable salt, hydrate, solvate, or polymorph thereof, wherein a compound of Formula II is treated with trimethylacetylene to yield, after removal of the TMS group under appropriate conditions, a compound of Formula IV which is reacted with a compound of Formula V R 1 -X V , in the presence of a suitable catalyst, such as PdCl 2 (PPh 3 ) 2 , to yield a compound of Formula I, which may be converted to a prodrug, pharmaceutically acceptable salt, hydrate, solvate, or polymorph.
  • a suitable catalyst such as PdCl 2 (PPh 3 ) 2
  • the carbon atom content of various hydrocarbon-containing moieties is indicated by a prefix designating the minimum and maximum number of carbon atoms in the moiety, i.e., the prefix C i-j indicates a moiety of the integer "i" to the integer "j" carbon atoms, inclusive.
  • (C 1-3 )alkyl refers to alkyl of one to three carbon atoms (i.e.
  • C 1-6 refers to a radical of one to six carbon atoms (i.e. 1, 2, 3, 4, 5 or 6 carbon atoms).
  • C 1-6 alkyl represents straight or branched chain alkyl groups. Examples of such alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec -butyl, and tert -butyl.
  • C 2-6 alkenyl represents straight or branched chain alkenyl groups.
  • C 1-6 alkoxy represents straight or branched chain -O-C 1-6 alkyl groups. Examples of such alkoxy groups include methoxy, ethoxy, n-propoxy, and isopropoxy, sec-butoxy, tert -butoxy.
  • acyl represents C 1-6 alkylcarbonyl, trifluoroacetyl, hydroxy-C 1-6 alkylcarbonyl, C 1-6 alkoxycarbonyl, N -C 1-6 alkylaminocarbonyl, N,N -di-(C 1-6 alkyl)aminocarbonyl (wherein the alkyl moieties may be optionally substituted by one or more halogen atoms), C 1-6 alkoxy-C 1-6 alkylcarbonyl, arylcarbonyl, heteroarylcarbonyl, cycloC 3-12 alkylcarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl, aryl-C 1-6 alkylcarbonyl, heteroaryl-C 1-6 alkylcarbonyl, arylamino-C 1-6 alkylcarbonyl, heteroarylamino-C 1-6 alkylcarbonyl, heterocyclylcarbonyl and heterocyclyl-C 1-6 alkylcarbonyl
  • cycloC 3-12 alkyl represents monocyclic or bicyclic, or tricyclic alkyl groups, including cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, bicyclo[2.2.1]heptyl and adamantanyl, which may be optionally substituted by one or more (e.g., 1, 2, 3, 4, or 5) substituents, which may be the same or different, selected independently from halogen, trifluoromethyl, trifluoromethoxy, C 1-6 alkyl, C 2-6 alkenyl, C 1-6 alkoxy, amino, hydroxy, cyano, C 1-6 alkoxycarbonyl, C 1-6 alkylamino, and di-(C 1-6 alkyl)amino, C 1-6 alkylcarbonylamino, oxo, C 1-6 alkoxyimino, N -C 1-6 alkylaminocarbonyl, N,N -di-(C 1-6 alkyl
  • cycloC 3-7 alkyl represents monocyclic alkyl groups, including cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl, which may be optionally substituted by one or more (e.g., 1, 2, 3, 4, or 5) substituents, which may be the same or different, selected independently from halogen, trifluoromethyl, trifluoromethoxy, C 1-6 alkyl, C 2-6 alkenyl, C 1-6 alkoxy, amino, hydroxy, cyano, C 1-6 alkoxycarbonyl, C 1-6 alkylcarbonyl, C 1-6 alkylamino, and di-(C 1-6 alkyl)amino, C 1-6 alkylcarbonylamino, oxo, C 1-6 alkoxyimino, N -C 1-6 alkylaminocarbonyl, N , N -di-(C 1-6 alkyl)aminocarbonyl, arylC 1-6
  • cycloC 5-12 alkenyl represents monocyclic or bicyclic, or tricyclic alkenyl groups, including cyclopentenyl, cyclohexenyl, and bicyclo[2.2.1]heptenyl, which may be optionally substituted by one or more (e.g., 1, 2, 3, 4, or 5) substituents, which may be the same or different, selected independently from halogen, fluoromethyl, difluoromethyl, trifluoromethyl, trifluoromethoxy, C 1-6 alkyl, C 2-6 alkenyl, C 1-6 alkoxy, amino, hydroxy, cyano, C 1-6 alkoxycarbonyl, C 1-6 alkylamino, and di-(C 1-6 alkyl)amino, C 1-6 alkylcarbonylamino, oxo, C 1-6 alkoxyimino, C 1-6 alkylaminocarbonyl, arylC 1-6 alkoxycarbonyl, and C 1-6 alkylened
  • aryl represents phenyl or naphthyl, wherein the phenyl or naphthyl group is optionally substituted by one or more (e.g., 1, 2, 3, 4, or 5) substituents, which may be the same or different, selected independently from halogen, fluoromethyl, difluoromethyl, trifluoromethyl, fluoromethoxy, difluoromethoxy, trifluoromethoxy, C 1-6 alkyl, hydroxyC 1-6 alkyl, C 2-6 alkenyl, C 1-6 alkoxy, C 1-6 alkylthio, C 1-6 alkoxyC 1-6 alkyl, amino, hydroxy, nitro, cyano, formyl, C 1-6 alkylcarbonyl, C 1-6 alkoxycarbonyl, C 1-6 alkylcarbonyloxy, C 1-6 alkylcarbonyloxyC 1-6 alkyl, C 1-6 alkylamino, di-(C 1-6 alkyl)amino, cycloC 3
  • heteroaryl represents an aromatic 5-6 membered ring containing from one to four heteroatoms selected from oxygen, sulfur and nitrogen, or a bicyclic group comprising a 5-6 membered ring containing from one to four heteroatoms selected from oxygen, sulfur and nitrogen fused with a benzene ring or a 5-6 membered ring containing from one to four heteroatoms selected from oxygen, sulfur and nitrogen, wherein the heteroaryl group may be optionally substituted by one or more (e.g., 1, 2, 3, 4, or 5) substituents, which may be the same or different, selected independently from halogen, fluoromethyl, difluoromethyl, trifluoromethyl, fluoromethoxy, difluoromethoxy, trifluoromethoxy, C 1-6 alkyl, hydroxyC 1-6 alkyl, C 2-6 alkenyl, C 1-6 alkoxy, C 1-6 alkylthio, amino, hydroxy, nitro, cyano, C 1-6 alkylcarbonyl
  • heteroaryl groups include furyl, thienyl, pyrrolyl, oxazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, pyrazolyl, triazolyl, thiadiazolyl, thiazolyl, imidazolyl, oxadiazolyl, tetrazolyl, pyridyl, pyrimidyl, pyridazinyl, pyrazinyl, triazinyl, purinyl, benzofuryl, benzothienyl, indolyl, indolizinyl, isoindolyl, indolinyl, indazolyl, benzimidazolyl, benzoxazolyl, benzothiazolyl, quinolinyl, quinazolinyl, quinoxalinyl, cinnolinyl, naphthyridinyl, isoquinolinyl, quinolizin
  • heterocyclyl represents a saturated or unsaturated non-aromatic 3 to 12 membered ring comprising one to four heteroatoms selected from oxygen, sulfur and nitrogen, and a saturated or unsaturated non-aromatic bicyclic ring system having 3 to 12 members comprising one to six heteroatoms selected from oxygen, sulfur and nitrogen, wherein the heterocyclic ring or ring system may be optionally substituted by one or more (e.g., 1, 2, 3, 4, or 5) substituents, which may be the same or different, selected independently from halogen, trifluoromethyl, fluoromethoxy, difluoromethoxy, trifluoromethoxy, C 1-6 alkyl, C 2-6 alkenyl, C 1-6 alkoxy, amino, hydroxy, nitro, cyano, C 1-6 alkoxycarbonyl, C 1-6 alkylcarbonyl, C 1-6 alkylamino, and di-(C 1-6 alkyl)amino, C 1-6 alkylcarbonylamin
  • halogen represents fluorine, chlorine, bromine and iodine.
  • the compounds of the present invention are usually named according to the IUPAC or CAS nomenclature system. Abbreviations which are well known to one of ordinary skill in the art may be used (e.g. "Ph” for phenyl, “Me” for methyl, “Et” for ethyl, “min” for minute or minutes, “h” for hour or hours, and “rt” for room temperature).
  • Memantine also known as 1-amino-3,5-dimethyladamantane, is disclosed, U.S. Patent Nos. 4,122,193 ; 4,273,774 ; and 5,061,703 , the subject matter of which patents is hereby incorporated by reference.
  • Memantine is a systemically-active noncompetitive NMDA receptor antagonists having moderate affinity for the receptor. It exhibits strong voltage dependent characteristics and fast blocking/unblocking kinetics (see e.g. Görtelmeyer et al., Arzneim-Forsch/Drug Res., 1992, 42:904-913 ; Winblad et al., Int. J. Geriat. Psychiatry, 1999, 14:135-146 ; Rogawski, Amino Acids, 2000, 19: 133-49 ; Danysz et al., Curr. Pharm. Des., 2002, 8:835-43 ; Jirgensons et. al. Eur. J. Med. Chem., 2000, 35: 555-565 ).
  • analog or “derivative” is used herein in the conventional pharmaceutical sense, to refer to a molecule that structurally resembles a reference molecule, but has been modified in a targeted and controlled manner to replace one or more specific substituents of the reference molecule with an alternate substituent, thereby generating a molecule which is structurally similar to the reference molecule.
  • Synthesis and screening of analogs e.g., using structural and/or biochemical analysis, to identify slightly modified versions of a known compound which may have improved or biased traits (such as higher potency and/or selectivity at a specific targeted receptor type, greater ability to penetrate blood-brain barriers, fewer side effects, etc.) is a drug design approach that is well known in pharmaceutical chemistry.
  • analogs and derivatives of the compounds of the invention may be created which have improved therapeutic efficacy, i.e., higher potency and/or selectivity at a specific targeted receptor type, either greater or lower ability to penetrate mammalian blood-brain barriers (e.g., either higher or lower blood-brain barrier permeation rate), fewer side effects, etc.
  • prodrug is used herein in the conventional pharmaceutical sense, to refer to a molecule which undergoes a transformation in vivo (e.g., an enzymatic or chemical transformation) to release an active parent drug.
  • Prodrugs of the compounds of Formula I of the present invention may be prepared by chemically modifying a functional group present in the compound of Formula I such that the chemically modified compound may undergo a transformation in vivo (e.g., enzymatic hydrolysis) to provide the compound of Formula I .
  • Examples of functional groups present in the compounds of Formula I which may be modified to produce prodrugs include carboxy, hydroxy, amino, and thio groups.
  • Prodrugs of the compounds of Formula I of the present invention may be prepared according to conventional techniques which have been described in the art (see, for example, Stella V., et al., Prodrugs: Challenges and Rewards, AAPS Press/Springer, New York, 2007 ).
  • compositions of the invention refers to molecular entities and other ingredients of such compositions that are physiologically tolerable and do not typically produce untoward reactions when administered to a mammal (e.g., human).
  • pharmaceutically acceptable may also mean approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in mammals, and more particularly in humans.
  • compositions of the present invention may be in the form of pharmaceutically acceptable salts.
  • “Pharmaceutically acceptable salts” refers to those salts which possess the biological effectiveness and properties of the parent compound and which are not biologically or otherwise undesirable. The nature of the salt is not critical, provided that it is non-toxic and does not substantially interfere with the desired pharmacological activity.
  • Compounds of general Formula I are prepared by Sonogashira coupling of fused bicyclic 3-bromopyridine derivatives 1 with substituted acetylenes in the presence of a suitable catalyst, such as Pd[PPh 3 ] 2 Cl 2 .
  • a suitable catalyst such as Pd[PPh 3 ] 2 Cl 2
  • fused bicyclic 3-bromopyridine derivatives 1 can be reacted with trimethylsilylacetylene in the presence of a suitable catalyst, such as Pd[PPh 3 ] 2 Cl 2 , to provide, after cleavage of TMS group, terminal acetylenes of general formula 2 .
  • Terminal acetylenes 2 can be reacted with aryl or heteroaryl bromides, iodides or triflates in Sonogashira coupling reactions in the presence of a suitable catalyst, such as Pd[PPh 3 ] 2 Cl 2 , to provide compounds of general Formula I .
  • a suitable catalyst such as Pd[PPh 3 ] 2 Cl 2
  • Fused bicyclic 3-bromopyridine derivatives 1 are either commercially available, prepared according to published procedures, or synthesized according to schemes depicted below.
  • fused bicyclic 3-bromopyridine derivatives 1 are conveniently prepared, e.g., by treament of ketones 3 with bromovinamidinium reagent 4 in the presence of an appropriate base, such as LiHMDS.
  • Substituted 7,8-dihydroquinolin-5(6 H )-ones 8 are synthetically accessible from hexane-1,3-dione derivatives 5 which are reacted with ammonium acetate to form 3-aminocyclohex-2-enone 6. This intermediate is converted to the desired 7,8-dihydroquinolin-5(6 H )-one 8 using 2-bromomalonaldehyde 7 .
  • Substituted 2 H -pyrano[2,3- b ]pyridin-4(3H)-one 13 may be prepared from 3,5-dibromo-2-methoxypyridine in three steps. Reaction with acrolein derivative 10 leads to the formation of alcohol 11 which is oxidized to the corresponding ketone 12 by means of manganese(IV) oxide. In the last step boron trichloride is used to furnish the desired 2 H -pyrano[2,3- b ]pyridin-4(3 H )-one derivative 13 .
  • Respective bicyclic 1-aza analogs 19 are synthesized starting from N- alkylation of 2-amino-5-bromopyridine 14 which is treated with acrylic acid to form intermediate 16 . Ring formation is accomplished by means of trifluoromethylsulfonic acid which leads to naphthyridine derivative 17 that can be further modified in 1-position by reaction with alkyl halides, acyl halides, chloroformates, sulfonyl or carbamoyl chlorides ( 18 ) to provide compounds of formula 19 .
  • Fused bicyclic 3-bromopyridines 20 are treated with sodium borohydride to provide corresponding alcohols 21 , which are subsequently methylated by means of methyl iodide in the presence of a suitable base, such as sodium hydride.
  • the final product 25 is formed in a Sonogashira coupling reaction using substituted acetylenes, a suitable palladium catalyst (e.g., Pd[PPh 3 ] 2 Cl 2 ), copper iodide, and tri- tert- butylphosphine.
  • reduction of the carbonyl group and methylation of the alcohol moiety may be performed after Sonogashira coupling towards acetylenes 23 to provide compounds of general formula 25.
  • 3-bromo-5,6,7,8-tetrahydro-1,6-naphthyridine 26 is acylated using acyl chlorides, chloroformates, sulfonyl or carbamoyl chlorides to provide derivatives 27 which are used for Sonogashira coupling with substituted acetylenes in the presence of a suitable catalyst, such as Pd[PPh 3 ] 2 Cl 2 , to yield compounds of general formula 30 .
  • 3-bromo-5,6,7,8-tetrahydro-1,6-naphthyridine 26 is protected with Boc group and coupled with substituted acetylenes in the presence of a suitable catalyst, such as Pd[PPh 3 ] 2 Cl 2 , to provide derivatives 28 .
  • the Boc group is cleaved with trifluoroacetic acid (TFA), and the obtained amines 29 are acylated using acyl chlorides, chloroformates, sulfonyl, or carbamoyl chlorides to provide compounds of general formula 30 .
  • 3-Bromo-7,8-dihydroquinolin-5(6 H )-one 31 is treated with trimethylsulfonium ylide to provide 3'-bromo-7',8'-dihydro-6' H -spiro[oxirane-2,5'-quinoline] 32 , treatment of which with Boc 2 O in the presence of a base provides 3'-bromo-7',8'-dihydro-6' H -spiro[oxazolidine-5,5'-quinolin]-2-one 33.
  • the free NH group in compound 33 can be alkylated with alkyl halides 34 in the presence of a base, such as NaH, to provide N -substituted derivatives 37 .
  • the epoxide in 3'-bromo-7',8'-dihydro-6' H -spiro[oxirane-2,5'-quinoline] 32 can be opened with primary amines 35 to give aminoalcohols 36 , which can be cyclized to N -substituted 3'-bromo-7',8'-dihydro-6' H -spiro[oxazolidine-5,5'-quinolin]-2-one derivatives 37 by treatment with carbonyldiimidazole (CDI).
  • CDI carbonyldiimidazole
  • 3-Bromo-7,8-dihydroquinolin-5(6 H )-one 31 is treated with hydroxylamine hydrochloride to form oxime 38 which is subsequently reacted with tosyl chloride towards intermediate product 39 .
  • the O -tosyl oxime moiety of 39 is rearranged to ⁇ -amino ketal 40 using a strong base, such as tert -butoxide.
  • the primary amino group of compound 40 is acylated with chloroacetyl chloride ( 41 ), and ring formation is accomplished by means of sodium hydroxide after reduction of the carbonyl group using L-selectride to provide tricyclic intermediate 43 .
  • the amide function of 43 is reduced by, e.g., lithium aluminium hydride to furnish [1,4]oxazino[2,3- f ]quinoline derivative 44 , which can be N -derivatized to compounds of general structure 45 by means of alkylating or acylating reagents, such as alkyl iodides or acyl chlorides.
  • aryl bromide 31 may be directly converted to the corresponding acetylene employing Sonogashira conditions followed by subsequent steps described in Scheme 7 to provide racemic compounds 46 .
  • Diastereomers may be separated by physical separation methods such as selective crystallization and chromatographic techniques, e.g. liquid chromatography using chiral stationary phases.
  • Enantiomers (optically active isomers) may be separated from each other by selective crystallization of their diastereomeric salts with optically active acids.
  • enantiomers may be separated by chromatographic techniques using chiral stationary phases.
  • Pure stereoisomeric forms may also be derived from the corresponding pure stereoisomeric form of appropriate starting materials, provided that the reaction occur stereoselectively.
  • Stereoisomeric forms of Formula I are included within the scope of this invention.
  • Compounds of Formula I which are marked by radioactive atoms may be obtained using art-known procedures. Typical compounds include those where one or more hydrogens are substituted by tritium, where one or more 12 C are substituted by 14 C where one or more fluor atoms are substituted by 18 F or other isotopes. These may be used for the treatment of diseases (e.g. cancer) but also for diagnostic purposes.
  • the radioactive atoms exchanged in the molecule are often isotopes of carbon, hydrogen, halogen, sulphur or phosphorus.
  • Compounds of the Formula I which are marked by radioactive atoms are included within the scope of this invention.
  • salts of the compounds of Formula I are those wherein the counterion is pharmaceutically acceptable.
  • salts of acids and bases which are non-pharmaceutically acceptable, may also find use, for example, in the preparation and purification of pharmaceutically acceptable compounds. All salts whether pharmaceutically acceptable or not are included within the ambit of the present invention.
  • the pharmaceutically acceptable salts as mentioned above are meant to comprise the therapeutically active non-toxic salt forms, which the compounds of Formula I are able to form. The latter may conveniently be obtained by treating the base form with such appropriate acids as inorganic acids, e.g.
  • hydrohalic acids such as hydrochloric, hydrobromic and the like; sulfuric acid; nitric acid; phosphoric acid and the like; or organic acids such as acetic, propanoic, hydroxyacetic, 2-hydroxypropanoic, oxopropanoic, oxalic, malonic, succinic, maleic, fumaric, malic, tartaric, 2-hydroxy-1,2,3-propanetricarboxylic, methanesulfonic, ethanesulfonic, benzenesulfonic, 4-methylbenzenesulfonic, cyclohexanesulfonic, 2-hydroxybenzoic, 4-amino-2-hydroxybenzoic and the like acids.
  • the salt form may be converted by treatment with alkali into the free base form.
  • the active ingredients of the compounds of the invention may be placed into the form of pharmaceutical compositions, unit dosages or dosage forms.
  • the pharmaceutical compositions may be employed as solid dosage forms, such as powders, granules, pellets, coated or uncoated tablets or filled capsules, or liquid dosage forms, such as solutions, suspensions, emulsions, or capsules filled with the same, or semi solid dosage forms, such as gels, creams and ointments.
  • the active ingredient(s) dissolution and release profiles of the pharmaceutical dosage forms may be varied from seconds to months.
  • compositions are designed for the use in animals and humans and may be applied via all application routes.
  • Preferred application routes will be the oral route, the dermal route, the pulmonary route, the nasal route, the rectal route, the parenteral route.
  • Such pharmaceutical compositions and unit dosage forms thereof may comprise conventional or new ingredients in conventional or special proportions, with or without additional active compounds or principles, and such unit dosage forms may contain any suitable effective amount of the active ingredient commensurate with the intended daily dosage range to be employed.
  • Tablets containing one (1) to one hundred (100) milligrams of active ingredient or, more broadly, zero point five (0.5) to five hundred (500) milligrams per tablet, are accordingly suitable representative unit dosage forms.
  • carrier applied to pharmaceutical compositions of the invention refers to a diluent, excipient, or vehicle with which an active compound is administered.
  • Such pharmaceutical carriers may be sterile liquids, such as water, saline solutions, aqueous dextrose solutions, aqueous glycerol solutions, and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like.
  • A.R. Gennaro, 20th Edition describes suitable pharmaceutical carriers in “Remington: The Science and Practice of Pharmacy ".
  • the active principles of the invention may be administered to a subject, e.g., a living animal (including a human) body, in need thereof, for the treatment, alleviation, or amelioration, palliation, or elimination of an indication or condition which is susceptible thereto, or representatively of an indication or condition set forth elsewhere in this application, preferably concurrently, simultaneously, or together with one or more pharmaceutically-acceptable excipients, carriers, or diluents, especially and preferably in the form of a pharmaceutical composition thereof, whether by oral, rectal, or parental (including intravenous and subcutaneous) or in some cases even topical route, in an effective amount.
  • Suitable dosage ranges are 1-1000 mg daily, optionally 10-500 mg daily, and optionally 50-500 mg daily, depending as usual upon the exact mode of administration, form in which administered, the indication toward which the administration is directed, the subject involved and the body weight of the subject involved, and the preference and experience of the physician or veterinarian in charge.
  • treat is used herein to mean to relieve or alleviate at least one symptom of a disease in a subject.
  • the term “treat” also denotes to arrest, delay the onset (i.e., the period prior to clinical manifestation of a disease) and/or reduce the risk of developing or worsening a disease.
  • compositions comprising a compound of the present invention and a second active ingredient (e.g., an NMDA receptor antagonist, L-DOPA, a dopaminomimetic, or a neuroleptic), in a formulation known in the art, or two separate pharmaceutical compositions (formulations), one comprising a compound of the present invention as formulated above and one comprising a second active ingredient (e.g., an NMDA receptor antagonist, L-DOPA, a dopaminomimetic, or a neuroleptic) in a formulation known in the art, to be administered conjointly.
  • a second active ingredient e.g., an NMDA receptor antagonist, L-DOPA, a dopaminomimetic, or a neuroleptic
  • the term “conjoint administration” is used to refer to administration of a compound of the present invention and a second active ingredient (e.g., an NMDA receptor antagonist, L-DOPA, a dopaminomimetic, or a neuroleptic) in one composition, or simultaneously in different compositions, or sequentially.
  • a second active ingredient e.g., an NMDA receptor antagonist, L-DOPA, a dopaminomimetic, or a neuroleptic
  • the sequential administration to be considered “conjoint”
  • the compound of the present invention and the NMDA receptor antagonist must be administered separated by a time interval that still permits the resultant beneficial effect in a mammal.
  • the compound of the present invention and the NMDA receptor antagonist must be administered on the same day (e.g., each - once or twice daily), including within an hour of each other, and including simultaneously.
  • terapéuticaally effective applied to dose or amount refers to that quantity of a compound or pharmaceutical composition that is sufficient to result in a desired activity upon administration to a living animal body in need thereof.
  • Compounds of the present invention may be administered orally, topically, parenterally, or mucosally (e.g., buccally, by inhalation, or rectally) in dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers. It is usually desirable to use the oral route.
  • the active agents may be administered orally in the form of a capsule, a tablet, or the like (see Remington: The Science and Practice of Pharmacy, 20th Editi on).
  • the orally administered pharmaceutical compositions may be administered in the form of a time-controlled release vehicle, including diffusion-controlled systems, osmotic devices, dissolution-controlled matrices, and erodible/degradable matrices.
  • the active drug component of Formula I may be combined with non-toxic, pharmaceutically acceptable excipients such as binding agents (e.g., pregelatinized maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g., lactose, sucrose, glucose, mannitol, sorbitol and other reducing and non-reducing sugars, microcrystalline cellulose, calcium sulfate, or calcium hydrogen phosphate); lubricants (e.g., magnesium stearate, talc, or silica, steric acid, sodium stearyl fumarate, glyceryl behenate, calcium stearate, and the like); disintegrants (e.g., potato starch or sodium starch glycolate); and/or wetting agents (e.g., sodium lauryl sulphate), coloring and flavoring agents, gelatin, sweeteners, natural and synthetic gums (such as acacia), e.g., acacia,
  • the drug components may be combined with non-toxic, pharmaceutically acceptable inert carriers (e.g., ethanol, glycerol, water), suspending agents (e.g., sorbitol syrup, cellulose derivatives or hydrogenated edible fats), emulsifying agents (e.g., lecithin or acacia), non-aqueous vehicles (e.g., almond oil, oily esters, ethyl alcohol or fractionated vegetable oils), preservatives (e.g., methyl or propyl-p-hydroxybenzoates or sorbic acid), and the like.
  • Stabilizing agents such as antioxidants (BHA, BHT, propyl gallate, sodium ascorbate, citric acid) may also be added to stabilize the dosage forms.
  • compositions of the invention containing as active compound a compound of Formula I may be also introduced in beads, microspheres or microcapsules, e.g., fabricated from polyglycolic acid/lactic acid (PGLA).
  • Liquid preparations for oral administration may take the form of, for example, solutions, syrups, emulsions or suspensions, or they may be presented as a dry product for reconstitution with water or other suitable vehicle before use. Preparations for oral administration may be suitably formulated to give controlled or postponed release of the active compound.
  • Liposome delivery systems such as small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles.
  • Liposomes may be formed from a variety of phospholipids, such as cholesterol, stearylamine or phosphatidylcholines, as is well known.
  • Compounds of the present invention may also be delivered by the use of monoclonal antibodies as individual carriers to which the compound molecules are coupled.
  • Active drugs may also be coupled with soluble polymers as targetable drug carriers.
  • Such polymers include polyvinyl-pyrrolidone, pyran copolymer, polyhydroxy-propyl methacrylamide-phenol, polyhydroxy-ethyl-aspartamide-phenol, or polyethyleneoxide-polylysine substituted with palmitoyl residues.
  • active drug may be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example, polylactic acid, polyglycolic acid, copolymers of polylactic and polyglycolic acid, polyepsilon caprolactone, polyhydroxybutyric acid, polyorthoesters, polyacetals, polyhydropyrans, polycyanoacrylates, and cross-linked or amphipathic block copolymers of hydrogels.
  • biodegradable polymers useful in achieving controlled release of a drug, for example, polylactic acid, polyglycolic acid, copolymers of polylactic and polyglycolic acid, polyepsilon caprolactone, polyhydroxybutyric acid, polyorthoesters, polyacetals, polyhydropyrans, polycyanoacrylates, and cross-linked or amphipathic block copolymers of hydrogels.
  • the therapeutics according to the present invention containing as active compound a compound of Formula I may be conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebulizer, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetra-fluoroethane, carbon dioxide, or other suitable gas.
  • a suitable propellant e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetra-fluoroethane, carbon dioxide, or other suitable gas.
  • the dosage unit may be determined by providing a valve to deliver a metered amount.
  • Capsules and cartridges of, e.g., gelatin for use in an inhaler or insufflator may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.
  • Formulations comprising compounds of the present invention may be delivered parenterally, i.e., by intravenous (i.v.), intracerebroventricular (i.c.v.), subcutaneous (s.c.), intraperitoneal (i.p.), intramuscular (i.m.), subdermal (s.d.), or intradermal (i.d.) administration, by direct injection, via, for example, bolus injection or continuous infusion.
  • Formulations for injection may be presented in unit dosage form, e.g., in ampoules or in multi-dose containers, with an added preservative.
  • compositions may take such forms as excipients, suspensions, solutions, or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.
  • the active ingredient may be in powder form for reconstitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.
  • Compounds of the present invention may also be formulated for rectal administration, e.g., as suppositories or retention enemas (e.g., containing conventional suppository bases such as cocoa butter or other glycerides).
  • rectal administration e.g., as suppositories or retention enemas (e.g., containing conventional suppository bases such as cocoa butter or other glycerides).
  • compositions containing a compound of Formula I may, if desired, be presented in a pack or dispenser device, which may contain one or more unit dosage forms containing the active ingredient and/or may contain different dosage levels to facilitate dosage titration.
  • the pack may, for example, comprise metal or plastic foil, such as a blister pack.
  • the pack or dispenser device may be accompanied by instructions for administration.
  • Compositions of the invention formulated in a compatible pharmaceutical carrier may also be prepared, placed in an appropriate container, and labeled for treatment of an indicated condition.
  • the dose of the components in the compositions of the present invention is determined to ensure that the dose administered continuously or intermittently will not exceed an amount determined after consideration of the results in test animals and the individual conditions of a patient.
  • a specific dose naturally varies depending on the dosage procedure, the conditions of a patient or a subject animal such as age, body weight, sex, sensitivity, feed, dosage period, drugs used in combination, seriousness of the disease.
  • the appropriate dose and dosage times under certain conditions may be determined by the test based on the above-described indices but may be refined and ultimately decided according to the judgment of the practitioner and each patient's circumstances (age, general condition, severity of symptoms, sex, etc.) according to standard clinical techniques.
  • Toxicity and therapeutic efficacy of the compositions of the invention may be determined by standard pharmaceutical procedures in experimental animals, e.g., by determining the LD 50 (the dose lethal to 50% of the population) and the ED 50 (the dose therapeutically effective in 50% of the population).
  • the dose ratio between therapeutic and toxic effects is the therapeutic index and it may be expressed as the ratio LD 50 /ED 50 .
  • Compositions that exhibit large therapeutic indices are preferred.
  • the instant compounds of Formula I represent a novel class of mGluR5 modulators. In view of their potency, they will be useful therapeutics in a wide range of disorders, in particular CNS disorders, which involve excessive glutamate induced excitation.
  • Neuroprotection as well as cognitive enhancement may also be achieved by administration of the instant compounds in combination with a NMDA receptor antagonist like Memantine.
  • the method-of-treating a living animal body with a compound of the invention, for the inhibition of progression or alleviation of the selected ailment therein, is as previously stated by any normally-accepted pharmaceutical route, employing the selected dosage which is effective in the alleviation of the particular ailment desired to be alleviated.
  • Use of the compounds of the present invention in the manufacture of a medicament for the treatment of a living animal for inhibition of progression or alleviation of selected ailments or conditions, particularly ailments or conditions susceptible to treatment with a Group I mGluR modulator is carried out in the usual manner comprising the step of admixing an effective amount of a compound of the invention with a pharmaceutically-acceptable diluent, excipient, or carrier, and the method-of-treating, pharmaceutical compositions, and use of a compound of the present invention in the manufacture of a medicament.
  • compositions prepared by admixing the active ingredient with a suitable pharmaceutically-acceptable excipient, diluent, or carrier include tablets, capsules, solutions for injection, liquid oral formulations, aerosol formulations, TDS formulations, and nanoparticle formulations, thus to produce medicaments for oral, injectable, or dermal use, also in accord with the foregoing.
  • MeCN is defined as acetonitrile, "CDI” as 1,1'-carbonyldiimidazole, “DBU” as 1,8-diazabicyclo[5.4.0]undec-7-ene, "DCM” as dichloromethane, “DME” as 1,2-dimethoxyethane, “DMF” as N,N -dimethylformamide, “EtOAc” as ethyl acetate, “LiHMDS” as lithium bis(trimethylsilyl)amide, "MeOH” as methanol, “TEA” as triethylamine, “TFA” as trifluoroacetic acid, and “THF” as tetrahydrofuran.
  • CDI 1,1'-carbonyldiimidazole
  • DBU 1,8-diazabicyclo[5.4.0]undec-7-ene
  • DCM dichloromethane
  • DME 1,2-dimethoxyethane
  • DMF 1,2-dime
  • 3-Bromo-5-methoxy-7,7-dimethyl-5,6,7,8-tetrahydroquinoline is prepared in close analogy to the procedure described above starting with 3-bromo-7,7-dimethyl-7,8-dihydroquinolin-5(6 H )-one.
  • a fused bicyclic 3-bromopyridine derivative (5.75 mmol, 1.0 eq), optionally substituted acetylene (8.62 mmol, 1.5 eq), copper( I )iodide (54 mg, 0.29 mmol, 0.05 eq), and, optionally, triphenylphosphine (45 mg, 0.17 mmol, 0.03 eq) are dissolved in 25 mL of anhydrous DMF.
  • the mixture is flushed thoroughly with argon.
  • PdCl 2 (Ph 3 P) 2 (121 mg, 0.17 mmol, 0.03 eq) and 3 mL of TEA are added, and the reaction mixture is stirred at 60 °C for 4 h (if not otherwise stated).
  • the reaction mixture is then diluted with water and extracted with chloroform. The organic extracts are combined, dried over anhydrous Na 2 SO 4 , and the solvent is evaporated.
  • the residue is purified by flash column chromatography or preparative HP
  • acyl chloride, chloroformate, sulfonyl or carbamoyl chloride (0.3 mmol) is slowly added to a solution of 3-(phenylethynyl)-5,6,7,8-tetrahydro-1,6-naphthyridine (35 mg, 0.15 mmol) or 3-bromo-5,6,7,8-tetrahydro-1,6-naphthyridine (32 mg, 0.15 mmol) and TEA (46 mg, 0.45 mmol) in dry DCM (2 mL).
  • reaction mixture is stirred at rt for 3 to 5 h, then diluted with NaHCO 3 solution, the organic phase is separated, dried over Na 2 SO 4 and concentrated in vacuo. The residue is purified by flash column chromatography on silica gel or preparative HPLC to provide title compound.
  • Trimethylsulfonium iodide (1.354 g, 6.63 mmol) is suspended in 15 mL THF, cooled to 0 °C, potassium tert -butylate (0.645 g, 5.76 mmol) solution in 15 mL THF is added, and the mixture is stirred at 0 °C for 10 min. Then a solution of 3-bromo-7,8-dihydroquinolin-5(6 H )-one (1.0 g, 4.42 mmol) in THF (15 mL) is added dropwise. The reaction mixture is stirred for additional 30 min at 0 °C, then allowed to warm to rt and stirred overnight. Water is added, and the mixture is extracted with EtOAc. The organic layer is washed with brine, dried over anhydrous Na 2 SO 4 , filtered and evaporated. The residue is purified by flash column chromatography to give the title compound (680 mg, 64%).
  • a primary amine (13.75 mmol) is added to a solution of 3'-bromo-7',8'-dihydro-6' H -spiro[oxirane-2,5'-quinoline] (660 mg, 2.75 mmol) in EtOH (5 mL), and the reaction mixture is heated in a closed vial to 80 °C for 15 h. The solvent is evaporated, and the residue is dissolved in dry THF (25 mL). CDI (2.23 g, 13.75 mmol) and TEA (1.40 g, 13.75 mmol) are added, and the mixture is stirred at rt for 15 h. Water is then added, and the mixture is extracted with EtOAc. The organic layer is washed with brine, dried over anhydrous Na 2 SO 4 , filtered and evaporated. The residue is purified by flash column chromatography to provide the title compound.
  • the obtained beige solid is dissolved in acetone (300 mL), diluted with water (100 mL) and treated with concentrated aqueous HCl solution (30 mL). The mixture is stirred at rt for 12 h and neutralized with an aqueous NaOH solution (10%). Acetone is removed at reduced pressure. The formed precipitate is collected by filtration, washed with water and crystallized from EtOAc/hexane to give N -(3-bromo-5-oxo-5,6,7,8-tetrahydroquinolin-6-yl)-2-chloroacetamide (8.69 g, 37%) as brownish solid.
  • LiAlH 4 (570 mg, 15.40 mmol) is added portionwise to a suspension of cis-9-bromo-4,4a,5,6-tetrahydro-2 H -[1,4]oxazino[2,3-f]quinolin-3(10b H )-one (2.40 g, 8.48 mmol) in dry THF (150 mL), and the resulting mixture is stirred at rt for 2 h. Then EtOAc (5 mL), EtOH (2 mL) and water (2 mL) are added to the mixture carefully. The reaction mixture is stirred for 30 min. The formed precipitate is filtered off and washed with DCM. The filtrate is concentrated at reduced pressure.
  • the obtained residue is purified by column chromatography (silica gel, DCM/EtOH, 20:1).
  • the resulting brown oil is diluted with MeCN (50 mL).
  • the insoluble by-product is filtered off and washed with cold MeCN (10 mL).
  • the filtrate is concentrated at reduced pressure and the residue is dried to yield the title compound (800 mg, 35%) as brown oil.
  • 9-Substituted 3,4,4a,5,6,10b-hexahydro-2 H -[1,4]oxazino[2,3-flquinolines are N- derivatized by means of an appropriate alkylating or acylating reagent, such as alkyl halogenides or carboxylic acid chlorides, in the presence of a suitable base, such as K 2 CO 3 or TEA ( Nozulak et al., J. Med. Chem. 1992, 35, 480-489 ), or by reductive amination methods using an appropriate aldehyde or ketone in the presence of NaBH(OAc) 3 ( Abdel-Magid et al., J. Org. Chem. 1996, 61, 3849-3862 ).
  • an appropriate alkylating or acylating reagent such as alkyl halogenides or carboxylic acid chlorides
  • a suitable base such as K 2 CO 3 or TEA
  • reaction mixture is allowed to reach rt, and the solution is stirred at 80 °C for 18 h. Then the mixture is allowed to cool to rt and partitioned between Et 2 O and a saturated aqueous NaHCO 3 solution (1:1). The layers are separated, and the aqueous layer is extracted with additional Et 2 O. The combined organic layers are washed with brine (2x), dried over Na 2 SO 4 and concentrated to give the crude product which is further purified by means of column chromatography or preparative HPLC, if necessary, to provide the final product.
  • 3-bromo-5-methoxy-7,7-dimethyl-5,6,7,8-tetrahydroquinoline (200 mg, 0.74 mmol) is reacted with 6-ethynylbenzene (163 ⁇ L, 1.48 mmol) in the presence of PdCl 2 [PPh 3 ] 2 (16 mg, 0.02 mmol), Cul (8 mg, 0.04 mmol), t-Bu 3 P (18 ⁇ L, 0.07 mmol), and TEA (1.50 mL, 10.70 mmol) in anhydrous MeCN (1.5 mL) under argon atmosphere at 80 °C for 1.5 h.
  • 3-bromo-5-methoxy-7,7-dimethyl-5,6,7,8-tetrahydroquinoline (396 mg, 1.46 mmol) is reacted with 6-ethynylpyridin-2-amine (293 mg, 2.46 mmol) in the presence of PdCl 2 [PPh 3 ] 2 (31 mg, 0.04 mmol), t -Bu 3 P (36 ⁇ L, 0.15 mmol), DBU (24 ⁇ L, 0.15 mmol), and Cs 2 CO 3 (482 mg, 1.48 mmol) in DMF (5 mL) under argon atmosphere at 200 °C for 1 h.
  • intermediate A 360 mg, 1.80 mmol
  • intermediate B 480 mg, 1.98 mmol
  • PdCl 2 [PPh 3 ] 2 63 mg, 0.09 mmol
  • t -Bu 3 P 18 mg, 0.09 mmol
  • DBU 27 mg, 0.18 mmol
  • TEA 2 mL
  • the crude product is purified by column chromatography (silica gel, hexane/EtOAc) to provide 3-(imidazo[1,2-a]pyridin-2-ylethynyl)-7,7-dimethyl-7,8-dihydroquinolin-5(6 H )-one (210 mg, 37%) as a yellowish solid, which is converted to the title compound in close analogy to the procedure described in Example 1 (yields: 95% after reduction, 17% after O-methylation).
  • 6-bromo-4-methoxy-2,2-dimethyl-3,4-dihydro-2 H -pyrano[2,3-b]pyridine 360 mg, 1.32 mmol
  • 6-ethynylpyridin-2-amine 172 mg, 1.45 mmol
  • PdCl 2 [PPh 3 ] 2 46 mg, 0.07 mmol
  • t-Bu 3 P 13 mg, 0.07 mmol
  • DBU 20 mg, 0.13 mmol
  • TEA 2 mL
  • the obtained residue is purified by column chromatography (silica gel, EtOAc/hexane) to yield the intermediate product 2-((trimethylsilyl)ethynyl)imidazo[1,2- a ]pyridine (1.23 g, 70%) as a light brown oil which is used on the next stage without further purification.
  • Acrylic acid (8.33 g, 115.6 mmol) is carefully added dropwise to a refluxing solution of 5-bromopyridin-2-amine (10.00 g, 57.80 mmol) in toluene (25 mL). The mixture is stirred at reflux for 3 days, concentrated at reduced pressure and diluted with aqueous KOH (6.47 g, 115.6 mmol) solution (150 mL). The formed solid is filtered, and the filtrate is extracted with DCM (3x). The aqueous phase is acidified to pH 5. The formed solid is collected by filtration, washed with water and dried to provide 3-((5-bromopyridin-2-yl)amino)propanoic acid (12.75 g, 90%) as beige solid.
  • t-Bu 3 P (51 mg, 0.25 mmol) is added to a solution of 6-bromo-2,3-dihydro-1,8-naphthyridin-4(1 H )-one (551 mg, 2.43 mmol) and TEA (3.7 mL) in DMF (3.5 mL) under argon atmosphere. The solution is stirred at rt for 5 min. Then PdCl 2 [PPh 3 ] 2 (51 mg, 0.07 mmol) is added, and the resulting mixture is stirred for 10 min.
  • the crude product is purified by column chromatography (silica gel, ethyl acetate/hexane, 1:2) to give intermediate cis -9-bromo-4-propyl-3,4,4a,5,6,10b-hexahydro-2 H -[1,4]oxazino[2,3- f ]quinoline (640 mg, 69%) as yellowish oil.
  • the title compound (110 mg, 61 %, yellow oil) is prepared according to the method described in Example 18 using cis -9-bromo-4-propyl-3,4,4a,5,6,10b-hexahydro-2 H -[1,4]oxazino[2,3- f ]quinoline (160 mg, 0.51 mmol) in the presence of TEA (0.5 mL), PdCl 2 [PPh 3 ] 2 (11 mg, 0.02 mmol), DBU (8 mg, 0.05 mmol), t -Bu 3 P (6 mg, 0.03 mmol), 1-ethynyl-3-fluorobenzene (101 mg, 0.84 mmol) and Cul (2 mg, 0.01 mmol) in MeCN (3 mL).
  • the title compound (69 mg, 39%, yellowish oil) is prepared according to the method described in Example 18 using cis -9-bromo-4-propyl-3,4,4a,5,6,10b-hexahydro-2 H -[1,4]oxazino[2,3- f ]quinoline (160 mg, 0.51 mmol) in the presence of TEA (0.5 mL), PdCl 2 [PPh 3 ] 2 (11 mg, 0.02 mmol), DBU (8 mg, 0.05 mmol), t -Bu 3 P (6 mg, 0.03 mmol), 1-ethynyl-4-fluorobenzene (101 mg, 0.84 mmol) and Cul (2 mg, 0.01 mmol) in MeCN (3 mL).
  • the reaction mixture is stirred at reflux for 5 h, cooled down to rt and concentrated at reduced pressure.
  • the residue is dissolved in EtOAc (10 mL) and hexane (20 mL) and washed with an aqueous HCl solution (5%, 3x30 mL).
  • the aqueous phases are combined, neutralized with KOH and extracted with DCM (3x30 mL).
  • the combined organic layers are dried over Na 2 SO 4 and concentrated at reduced pressure.
  • the residue is purified by column chromatography (silica gel, ethyl acetate/hexane, 1:3) followed by preparative HPLC (C18, MeCN/water) to provide the title compound (83 mg, 47%) as a yellowish oil.
  • the title compound (obtained as off-white solid HCl salt) is prepared in close analogy to the procedure described in Example 15 starting with trans -9-(phenylethynyl)-3,4,4a,5,6,10b-hexahydro-2 H -[1,4]oxazino[2,3- f ]quinoline which is accessible via the method described in Preparation 5 and 6 using NaBH 4 in MeOH instead of L-selectride for the reduction of the ketone intermediate 2-chloro- N -(5-oxo-3-(phenylethynyl)-5,6,7,8-tetrahydroquinolin-6-yl)acetamide.
  • Trifluoromethanesulfonic anhydride (3.29 mL, 19.60 mmol) is added dropwise to a mixture of 2,2,2-trifluoroethanol (1.24 mL, 17.00 mmol) and pyridine (1.36 mL, 19.60 mmol) in anhydrous DCM (10 mL) at 0 °C over 15 min. The resulting mixture is stirred at 0 °C for 1 h and diluted with water (5 mL). The organic layer is separated and dried over Na 2 SO 4 . The obtained solution of 2,2,2-triluoroethyl trifluoromethanesulfonate (1.00 mL, approx.
  • N -Methyl morpholine (0.17 mL, 1.50 mmol) and methyl chloroformate (97 mg, 1.03 mmol) are added dropwise to a solution of cis -9-(phenylethynyl)-3,4,4a,5,6,10b-hexahydro-2 H -[1,4]oxazino[2,3- f ]quinoline (200 mg, 0.69 mmol) in anhydrous DCM (7 mL).
  • the reaction mixture is stirred at rt for 1 h and diluted with water (30 mL) and DCM (50 mL). The organic layer is separated, dried over Na 2 SO 4 and concentrated at reduced pressure.
  • Methyl formate (159 mg, 2.65 mmol, 2 eq.) is added to a suspension of 120 mg of NaH (80% in mineral oil) (95 mg, 3.98 mmol, 3 eq.) in 6 mL of dry Et 2 O. The resulting mixture is heated to reflux and 3-bromo-7,8-dihydroquinolin-5(6 H )-one (300 mg, 1.33 mmol, 1 eq.), followed by a drop of methanol are added. The mixture is refluxed for 6 h and then stirred at rt overnight. The reaction mixture is diluted with DCM and water and AcOH is added to pH ⁇ 5. The organic layer is separated, and the aqueous layer is extracted with DCM (2 times).
  • tert -butyl 6-oxooctahydro-1 H -indole-1-carboxylate (1.00 g, 4.18 mmol) is reacted with N -(2-bromo-3-(dimethylamino)allylidene)- N -methylmethanaminium hexafluorophosphate, and the crude product is purified by flash column chromatography (silica, gradient 20% to 70% EtOAc/heptane) to yield a mixture of tert -butyl 8-bromo-2,3,3a,4,5,9b-hexahydro-1 H- pyrrolo[2,3- f ]quinoline-1-carboxylate and tert -butyl 6-bromo-2,3,3a,4,9,9a-hexahydro-1 H -pyrrolo[3,2- g ]quinoline-1-carboxylate which is used as such in the next reaction step.
  • Boc-deprotection is accomplished according to the procedure described in Example 29. Then, TEA (0.317 mL, 2.271 mmol) is added to a cooled solution (0 °C) of the obtained crude intermediate 3-bromo-6,6a,7,8,9,9a-hexahydro-5 H -pyrrolo[3,4- h ]quinoline 2,2,2-trifluoroacetate in DCM (3 mL), immediately followed by the addition of methyl chloroformate (0.070 mL, 0.909 mmol). After stirring at 0 °C for 3 h a saturated aqueous solution of NaHCO 3 (10 mL) is added, and the mixture is stirred for 0.5 h.
  • the crude product is purified by flash column chromatography (Grace pre-packed column, silica 4 g, gradient 25% to 75% EtOAc/heptane) to give an oil, which is crystallized from pentane/Et 2 O to provide the title compound (26 mg, 41 %) as brown crystals.
  • 3-bromo-5,6,7,8-tetrahydro-1,6-naphthyridine is acylated with pivaloyl chloride to provide 1-(3-bromo-7,8-dihydro-1,6-naphthyridin-6(5 H )-yl)-2,2-dimethylpropan-1-one, which is coupled with 6-ethynylpyridin-2-amine according to General Procedure 1 to provide the title compound as a colorless solid.
  • 3-bromo-5,6,7,8-tetrahydro-1,6-naphthyridine (213 mg, 1.00 mmol) is acylated with ethyl chloroformate (163 mg, 1.50 mmol) in the presence of TEA (347 mg, 3.43 mmol) and DMAP (15 mg, 0.12 mmol) to provide ethyl 3-bromo-7,8-dihydro-1,6-naphthyridine-6(5 H )-carboxylate which is coupled with ethynylbenzene in the presence of TEA (1.6 mL), t -Bu 3 P (17 mg, 0.084 mmol) and PdCl 2 [PPh 3 ] 2 (17 mg, 0.024 mmol) in anhydrous MeCN (10 mL) according to General Procedure 1 to provide the title compound (67 mg, 28%) as a yellowish solid.
  • tert-butyl 3-bromo-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylate is coupled with 1-ethynyl-3-fluorobenzene to provide, after removal of the Boc group, 3-((3-fluorophenyl)ethynyl)-5,6,7,8-tetrahydro-1,6-naphthyridine, which is then acylated with dimethylcarbamic chloride according to General Procedure 2, to provide the title compound as a colorless solid.
  • tert -butyl 3-bromo-7,8-dihydro-1,6-naphthyridine-6(5 H )-carboxylate is coupled with 3-ethynylbenzonitrile to provide, after removal of the Boc group, 3-((5,6,7,8-tetrahydro-1,6-naphthyridin-3-yl)ethynyl)benzonitrile, which is then acylated with dimethylcarbamic chloride according to General Procedure 2, to provide the title compound as a colorless solid.
  • tert-butyl 3-bromo-7,8-dihydro-1,6-naphthyridine-6(5 H )-carboxylate is coupled with 6-ethynylpyridin-2-amine to provide, after removal of the Boc group, 6-((5,6,7,8-tetrahydro-1,6-naphthyridin-3-yl)ethynyl)pyridin-2-amine, which is then acylated with dimethylcarbamic chloride according to General Procedure 2, to provide the title compound as a colorless solid.
  • tert -butyl 3-bromo-7,8-dihydro-1,6-naphthyridine-6(5 H )-carboxylate is coupled with 3-ethynylbenzonitrile to provide, after removal of the Boc group, 3-((5,6,7,8-tetrahydro-1,6-naphthyridin-3-yl)ethynyl)benzonitrile, which is then acylated with diethylcarbamic chloride according to General Procedure 2, to provide the title compound as a colorless solid.
  • tert -butyl 3-bromo-7,8-dihydro-1,6-naphthyridine-6(5 H )-carboxylate is coupled with 3-ethynylbenzonitrile to provide, after removal of the Boc group, 3-((5,6,7,8-tetrahydro-1,6-naphthyridin-3-yl)ethynyl)benzonitrile, which is then acylated with piperidine-1-carbonyl chloride according to General Procedure 2, to provide the title compound as a colorless solid.
  • CDI (2.80g, 17.24 mmol) is suspended in 15 mL of dry DCM, the mixture is cooled in the ice bath and 3,3-diethoxy- N -methylpropan-1-amine ( Synthesis 1995; 1995(5), p. 592-604 ), (2,78 g, 17,24 mmol) is added. After 30 min the ice bath is removed and the mixture is stirred overnight. The mixture is partitioned between DCM and water, the organic layer is separated, dried over anhydrous Na 2 SO 4 , filtered and evaporated to give 3.55 g (80%) of sufficiently pure N -(3,3-diethoxypropyl)- N -methyl-1 H -imidazole-1-carboxamide as red oil.
  • But-3-en-1-amine (492 mg, 6.92 mmol) is dissolved in DCM (20 mL), and this solution is added to a suspension of 1-((3,3-diethoxypropyl)(methyl)carbamoyl)-3-methyl-1 H -imidazol-3-ium iodide (5.50 g, 13.85 mmol) in DCM (10 mL), followed by addition of TEA (3.50 g, 34.61 mmol). The mixture is stirred overnight at rt, then partitioned between DCM and sat. aq. NaHCO 3 solution. The organic phase is separated, dried over anhydrous Na 2 SO 4 , filtered and evaporated. The residue is purified by flash column chromatography on silica gel to give 3-(but-3-en-1-yl)-1-(3,3-diethoxypropyl)-1-methylurea (820 mg, 46%) as a yellow oil.
  • methyl 3-oxo-8-azabicyclo[3.2.1]octane-8-carboxylate (accessible by acylation of 8-azabicyclo[3.2.1]octan-3-one with methyl chloroformate or as described by Kamogawa et al., Heterocycles 2010, 82, 325-332 ) (250 mg, 1.365 mmol) is reacted with N -(2-bromo-3-(dimethylamino)allylidene)- N- methylmethanaminium hexafluorophosphate, and the crude product is purified by flash column chromatography (silica, gradient 20% to 70% EtOAc/heptane) to provide the intermediate product methyl 3-(phenylethynyl)-6,7,8,9-tetrahydro-5 H -5,8-epiminocyclohepta-[ b ]pyridine-10-carboxylate (179 mg, 44%) as a yellow oil.
  • the black suspension is flushed with hydrogen (3 evacuate/refill cycles) and stirred at rt under hydrogen (balloon) for 18 h, followed by 3 h at 40 °C.
  • the reaction mixture is flushed with nitrogen for 30 min and filtered over kieselguhr.
  • the filter cake is rinsed with EtOH (2x50 mL).
  • reaction mixture is diluted with DCM (50 mL) and washed with a saturated aqueous NaHCO 3 solution (50 mL) and brine (50 mL).
  • the organic phase is dried over Na 2 SO 4 , filtered and concentrated to give a yellow oil.
  • Purification by flash column chromatography (silica, gradient 5% to 25% EtOAc/heptane) affords the intermediate product rac- cis methyl 4-oxooctahydro-1 H -cyclopenta[b]pyridine-1-carboxylate (398 mg, 53% over two steps) as a light yellow oil.
  • the crude product is purified by flash column chromatography (silica, first gradient 2% to 20% DME/heptane, followed by gradient 2% to 20% EtOAc/heptane) to provide the title compound (35 mg, 42%) as a colorless viscous oil.
  • the crude product is purified by flash column chromatography (silica, first gradient 2% to 20% EtOAc/heptane, followed by a second gradient of 2% to 20% DME/heptane) to provide the title compound (55 mg, 56%) as a light yellow viscous oil.
  • the crude product is purified by flash column chromatography (silica, first gradient 2% to 20% EtOAc/heptane, followed by a second gradient of 2% to 20% DME/heptane) to provide the title compound (65 mg, 70%) as a light yellow viscous oil.
  • 4-Nitrophenyl chloroformate (103 mg, 0.51 mmol) is added dropwise to a mixture of cis-9-(phenylethynyl)-3,4,4a,5,6,10b-hexahydro-2 H -[1,4]oxazino[2,3- f ]quinoline (135 mg, 0.46 mmol) and TEA (0.84 mL, 6.00 mmol) in dry THF (3 mL) at rt. The mixture is stirred at rt for 30 min. Then azetidine hydrochloride (300 mg, 3.19 mmol) is added.
  • the reaction mixture is stirred at 50 °C for 4 h, allowed to stand at rt for 16 h, diluted with water and extracted with EtOAc (3x50 mL). The combined organic phases are washed with a saturated aqueous K 2 CO 3 solution (3x30 mL), dried over Na 2 SO 4 and concentrated at reduced pressure. The obtained residue is purified by column chromatography (silica gel, EtOAc/EtOH, 30:1) to provide the title compound (82 mg, 48%) as a brownish oil.
  • reaction mixture is stirred at rt for 30 min, then transferred to a mixture of NH 4 OAc (3.31 g, 43.0 mmol), AcOH (2.46 mL, 43.0 mmol) and THF (1mL).
  • the reaction mixture is then heated to reflux for 4h, then allowed to cool to rt and partitioned between Et 2 O and saturated aqueous NaHCO 3 solution.
  • Et 2 O saturated aqueous NaHCO 3 solution
  • the layers are separated, and the aqueous layer is extracted with additional Et 2 O.
  • the combined organic layers are washed with brine, dried over Na 2 SO 4 and concentrated.
  • the residue is purified by flash column chromatography, to give 0.67 g (34 %) of 3-bromo-7,8-dihydro-5H-thiopyrano[4,3-b]pyridine as a brown oil.
  • Aziridine (16.9 g, 0.39 mol) is dissolved in MeOH (500 mL) and treated with cyclohex-2-enone (45.4 g, 0.47 mol) at rt. Copper (25.0 g, 0.39 mol) is added, and the solution is stirred for 3 h, filtered and evaporated to dryness.
  • the crude intermediate product is purified by column chromatography (silica gel, petrol ether/EtOAc 1:1) to give 3-(aziridin-1-yl)cyclohexanone (39.3 g, 72%) as a yellow oil.
  • TEA 35 mL, 252 mmol
  • methyl chloroformate 2.4 mL, 31.1 mmol
  • the mixture is concentrated in vacuo and dissolved in DCM (100 mL).
  • the organic layer is washed with a mixture of saturated aqueous NaHCO 3 solution and water (1:1, 100 mL).
  • the aqueous layer is then extracted with DCM (2x75 mL).
  • the organic layers are combined, washed with brine (100 mL), dried over Na 2 SO 4 and concentrated in vacuo.
  • Methyl 7-hydroxyoctahydro-1 H -indole-1-carboxylate (1.19 g, 5.97 mmol) is dissolved in DCM (100 mL), followed by the addition of Dess-Martin periodinane (3.04 g, 7.17 mmol), and the dark brown solution is stirred at rt. After stirring for 30 min, 10% aqueous Na 2 S 2 O 3 solution (100 mL) is added, and the mixture is vigorously stirred for another 30 min. The layers are separated, and the organic layer is diluted with DCM (50 mL), washed with brine (100 mL), dried over Na 2 SO 4 and concentrated in vacuo.
  • the crude product is purified by flash column chromatography (adsorbed onto hydromatrix, silica, gradient 100% heptane to 80% EtOAc/heptane) to provide the title compound (103 mg, 80%) as a brown paste.
  • the instant compounds may be processed into tablets, coated tablets, capsules, drip solutions, suppositories, injection and infusion preparations, and the like and may be therapeutically applied by the oral, rectal, parenteral, and additional routes.
  • Representative pharmaceutical compositions according to the present invention follow:
  • a suitable formulation for a tablet containing 10 milligrams of active ingredient is as follows: mg Active Ingredient 10 Lactose 61 Microcrystalline Cellulose 25 Talcum 2 Magnesium stearate 1 Colloidal silicon dioxide 1
  • Another suitable formulation for a tablet containing 100 mg is as follows: mg Active Ingredient 100 Polyvinylpyrrolidone, crosslinked 10 Potato starch 20 Polyvinylpyrrolidone 19 Magnesium stearate 1 Microcrystalline Cellulose 50 Film coated and colored.
  • the film coating material consists of: Hypromellose 10 Microcryst. Cellulose 5 Talcum 5 Polyethylene glycol 2 Color pigments 5
  • a suitable formulation for a capsule containing 50 milligrams of active ingredient is as follows: mg Active Ingredient 50 Corn starch 26 Dibasic calcium phosphate 50 Talcum 2 Colloidal silicon dioxide 2 filled in a gelatin capsule.
  • a suitable formulation for an injectable solution is as follows: Active Ingredient mg 10 Sodium chloride mg q.s. Water for Injection mL add 1.0
  • a suitable formulation for 1 liter of a an oral solution containing 2 milligrams of active ingredient in one milliliter of the mixture is as follows: mg Active Ingredient 2 Saccharose 250 Glucose 300 Sorbitol 150 Orange flavor 10 Colorant q.s. Purified water add 1000 mL
  • Another suitable formulation for 1 liter of a liquid mixture containing 20 milligrams of active ingredient in one milliliter of the mixture is as follows: G Active Ingredient 20.00 Tragacanth 7.00 Glycerol 50.00 Saccharose 400.00 Methylparaben 0.50 Propylparaben 0.05 Black currant-flavor 10.00 Soluble Red color 0.02 Purified water add 1000 mL
  • Another suitable formulation for 1 liter of a liquid mixture containing 2 milligrams of active ingredient in one milliliter of the mixture is as follows: G Active Ingredient 2 Saccharose 400 Bitter orange peel tincture 20 Sweet orange peel tincture 15 Purified water add 1000 mL
  • 180 g aerosol solution contain: G Active Ingredient 10 Oleic acid 5 Ethanol 81 Purified Water 9 Tetrafluoroethane 75 15 ml of the solution are filled into aluminum aerosol cans, capped with a dosing valve, purged with 3.0 bar.
  • 100 g solution contain: G Active Ingredient 10.0 Ethanol 57.5 Propyleneglycol 7.5 Dimethylsulfoxide 5.0 Hydroxyethylcellulose 0.4 Purified water 19.6 1.8 ml of the solution are placed on a fleece covered by an adhesive backing foil. The system is closed by a protective liner which will be removed before use.
  • polybutylcyanoacrylate nanoparticles contain: G Active Ingredient 1.00 Poloxamer 0.10 Butylcyanoacrylate 8.75 Mannitol 0.10 Sodium chloride 0.05
  • Polybutylcyanoacrylate nanoparticles are prepared by emulsion polymerization in a water/0.1 N HCl/ethanol mixture as polymerizsation medium. The nanoparticles in the suspension are finally lyophilized under vacuum.
  • 1.0 g of the suspension contains the following: g Active Ingredient 0.10 Hypromellose 0.01 Purified water Ad 1.0 g
  • Hypromellose is dispersed in water homogeneously with a high speed mixer/blender. After about one hour of hydration time of the hypromellose, the active ingredient is blended homogeneously into the hypromellose solution. The viscosity of the suspension may be adjusted by the amount of hypromellose, resulting in a very stable suspension with a very slow tendency of particle sedimentation and particle agglomeration.
  • 1.0 ml of solution contain: g Active Ingredient 0.05 Mannitol q.s. DMSO 0.10 Water for injection Ad 1.0 ml
  • the active ingredient is dissolved in DMSO by stirring and heating (solution 1).
  • the mannitol is dissolved in WFI (solution 2).
  • solution 1 After cooling down to rt solution 1 is mixed with solution 2 by continuous stirring.
  • the solution is sterilized by filtration of by autoclaving.
  • the active principles of the present invention, and pharmaceutical compositions containing them and method of treating therewith, are characterized by unique and advantageous properties.
  • the compounds and pharmaceutical compositions thereof exhibit, in standard accepted reliable test procedures, the following valuable properties and characteristics.
  • Tissue preparation is performed according to Foster & Wong (Br. J. Pharmacol., 1987, 91, 403-409 ) with some modifications.
  • Anaesthetised male Sprague-Dawley rats (200-250 g, Janvier, Le Genest-Isle, France) are decapitated and their brains are removed rapidly.
  • the cortex is dissected out and processed as described by Parsons, et al. (J. Pharmacol. Exp. Ther., 1997, 283(3): 1264-1275 ).
  • the cortices are homogenized in 20 volumes of ice-cold 0.32 M sucrose (Sigma-Aldrich, Taufkirchen, Germany) using a glass-Teflon homogenizer.
  • the homogenate is centrifuged at 1000 x g for 10 minutes, the pellet is discarded and the supernatant centrifuged at 20,000 x g for 20 minutes.
  • the resulting pellet is resuspended in 20 volumes of distilled water and centrifuged for 20 minutes at 8000 x g.
  • the supernatant and the buffy coat are then centrifuged six times (48,000 x g for 20 minutes) in the presence of 5 mM Tris-HCl, pH 7.5. All centrifugation steps are carried out at 4°C. After resuspension in 5 volumes of 5 mM Tris-HCl, pH 7.5, the membrane suspension is frozen rapidly at -80°C.
  • the membrane suspensions are thawed, centrifuged (48,000 x g for 20 minutes) and then resuspended in 50 mM Tris-HCl, pH 7.5 (assay buffer).
  • the amount of protein in the final membrane preparation is determined according to the method of Lowry, et al. (J. Biol. Chem., 1951, 193, 256-275 ).
  • the final concentration used for our studies is 400 ⁇ g / ml.
  • the Tecan robotic system designed for binding assays is loaded with the membrane solution, a 96 well stock plate containing the solutions for bound control (buffer/DMSO 10%), unlabeled MPEP (10 ⁇ M) for evaluation of non-specific binding, all compounds to be tested (at 20-fold concentrations), various empty 96-well plates for dilutions and the final assay plates, as well as a 96-well plate filled with the radioligand.
  • the assay plates are loaded with membrane solution and are shaken at 4°C.
  • the compounds are added (including the non-specific binding control containing MPEP).
  • the final DMSO concentration is always 1 %.
  • the assay plates are incubated and shaken at 4°C for 1 h, before the mixture is exhausted as rapidly as possible via a vacuum manifold using the Multiscreen HTS glass fibre (type B) high flow filter plates (Millipore, Schwalbach, Germany) under a constant vacuum of 450 mbar.
  • the membranes are washed four times with cold assay buffer (100 ⁇ L).
  • the measured radioactivity of the radioligand alone was set as 100% bound control and the non-specific binding of the radioligand represented the 0% control.
  • the residual radioactivity after displacement of the test compound was then corrected with respect to the set controls. Data are given as median IC 50 and K i , respectively.
  • CHO-K1 cells Chinese hamster ovary cells (CHO-K1 cells), stably transfected for inducible expression of a human metabotropic glutamate receptor mGluR5 to form a cell line called h5CHO, are seeded into black clear bottom 96 well plates at a density of 35.000 cells per well.
  • the standard growth medium used (Dulbecco's modified Eagle Medium, DMEM plus L-proline) contains the appropriate inducer isopropyl- ⁇ -D-thiogalactopyranosid (IPTG) to achieve optimal receptor expression.
  • IPTG inducer isopropyl- ⁇ -D-thiogalactopyranosid
  • One day after seeding the growth medium is exchanged for reconstituted Ca-Kit (Molecular Devices, USA) and incubated for one hour.
  • Ca-Kit is reconstituted in an assay buffer containing 20 mM HEPES pH 7.4, glutamic-pyruvate transaminase, pyridoxal phosphate and sodium pyruvate in Hank's balanced salt solution (HBBS).
  • HBBS Hank's balanced salt solution
  • Agonistic compounds to the receptor elicit increases in cytosolic calcium which can be measured as increases in fluorescence signals by use of a fluorescence imaging plate reader (Molecular Devices).
  • a fluorescence imaging plate reader Molecular Devices.
  • To analyze their potency to negatively modulate the Ca-response test compounds dissolved in a final DMSO concentration of 0.5%, are added on-line 5 minutes before the agonist to the receptor (L-quisqualic acid at a concentration giving ⁇ 80% of the maximal signal).
  • EC 50 values for positive allosteric modulators were determined by stimulating the cells which have been preincubated the modulators by an EC 20 concentration of L-glutamate.
  • astrocyte cultures are prepared from cortices of newborn rats as described by Booher and Sensenbrenner (1972, Neurobiology 2(3):97-105 ). Briefly, Sprague-Dawley rat pups (2 - 4 d old) are decapitated and neocortices are dissected, disintegrated with a nylon filter (pore size 80 ⁇ m) and carefully triturated.
  • the cell suspension is plated on poly-D-lysine pre-coated flasks (Costar, Netherlands) and cultivated in Dulbecco's Modified Eagle's Medium (DMEM, Invitrogen, Germany) supplemented with 10% foetal calf serum (FCS, Sigma, Germany), 4 mM glutamine and 50 ⁇ g/ml gentamycin (both Biochrom, Germany) at 37°C in a humidified atmosphere of 5% CO 2 / 95% air for 7 days with exchanging the medium at day 2 and 6.
  • DMEM Dulbecco's Modified Eagle's Medium
  • FCS foetal calf serum
  • FCS foetal calf serum
  • 4 mM glutamine 50 ⁇ g/ml gentamycin (both Biochrom, Germany) at 37°C in a humidified atmosphere of 5% CO 2 / 95% air for 7 days with exchanging the medium at day 2 and 6.
  • astrocytes are rinsed twice with CMF-PBS (calcium- and magnesium-free phosphate buffered saline, Biochrom, Germany), trypsinized and subplated on poly-D-lysine pre-coated 96-well plates (Greiner, Germany) at a density of 40,000 cells/well.
  • CMF-PBS calcium- and magnesium-free phosphate buffered saline, Biochrom, Germany
  • astrocytes are rinsed with PBS ++ (phosphate buffered saline, Biochrom, Germany) and fed with astrocyte-defined medium (ADM) consisting of DMEM containing 1x G5-supplement (Invitrogen, Germany), 0.5 ⁇ g/ml heparan sulfate, and 1.5 ⁇ g/ml fibronectin (both Sigma, Germany) ( Miller et al., (1993) Brain Res. 618(1):175-8 ). 3 days later the medium is exchanged and the cells incubated for another 2-3 days, so that at the time of experiments astrocytes are 14-15 DIV.
  • ADM astrocyte-defined medium
  • Immunostaining is performed to confirm the presence of astrocytic markers such as the glial fibrillary acidic protein (GFAP) as well as to monitor the expression of mGluR5 receptors.
  • astrocytic markers such as the glial fibrillary acidic protein (GFAP) as well as to monitor the expression of mGluR5 receptors.
  • the increase of cytosolic calcium after stimulation with the mGluR5 agonist L-quisqualate is measured using a fluorometric imaging plate reader (FLIPR) and the Ca-Kit (both Molecular Devices).
  • FLIPR fluorometric imaging plate reader
  • the medium Prior to addition of agonist or antagonist the medium is aspirated and cells are loaded for 2 h at RT with 150 ⁇ l of loading buffer consisting of Ca-sensitive dye reconstituted in sodium chloride (123 mM), potassium chloride (5.4 mM), magnesium chloride (0.8 mM), calcium chloride (1.8 mM), D-glucose (15 mM), and HEPES (20 mM), pH 7.3.
  • concentration-response curves for quisqualate are performed in the presence and absence of 10 ⁇ M modulator to determine the extent of potentiation / agonist potency increase. Thereafter, concentration-response curves for the positive modulator are performed in the presence of a fixed concentration of quisqualate showing the biggest window for potentiation (normally 10-30 nM).
  • MaxMin maximum minus minimum
  • EC 50 and IC 50 are calculated according the logistic equation using XLFit (IDBS, UK) or Prism 4.0 (GraphPad Software, USA).
  • the compounds of the present invention have a potency (EC 50 or IC 50 ) within a range of about 0.5 nM to about 100 ⁇ M.
  • the left shifts for positive or slient allosteric modulators (PAMs or SAMs, respectively) are determined by comparison of EC 50 values from agonist dose response curves run in the presence of 10 ⁇ M modulator or vehicle ( Vanejevs et al., J. Med. Chem., 2008, 51, 634-647 ).
  • the compounds of the present invention show show an affinity to the allosteric site, i.e., the MPEP site, shown by the displacement of the radioligand [ 3 H]-MMPEP.
  • Negative allosteric modulators which inhibit the calcium signals of mGluR5 orthostatic ligands
  • PAMs positive allosteric modulators
  • SAMs silent allosteric modulators
  • Tables A1-A3 Compound Chemical Name hEC 50 [ ⁇ M] h left shift rEC 50 [ ⁇ M] r left shift
  • Example 1 ( rac )-5-Methoxy-3-(phenylethynyl)-5,6,7,8-tetrahydroquinoline 0.0321 2.6-fold 0.0227 4.9-fold
  • Example 2 ( R )- or (S)-5-Methoxy-3-(phenylethynyl)-5,6,7,8-tetrahydroquinoline 0.0209 2.3-fold 0.0125 4.4-fold
  • Example 10 ( rac )-3'-(Phenylethynyl)-7',8'dihydro-6' H -spiro[oxazolidine-5,5'-quinolin]-2-one n.d.
  • Example 11 ( rac )-3-Methyl-3'-(phenylethynyl)-7',8'-dihydro-6' H -spiro[oxazolidine-5,5'-quinolin]-2-one 0.0537 1.8-fold 0.0586 2.9-fold
  • Example 12 ( rac )-3-Phenyl-3'-(phenylethynyl)-7',8'-dihydro-6' H -spiro[oxazolidine-5,5'-quinolin]-2-one 0.966 1.9-fold 0.856 n.d.
  • Example 14 ( rac )- cis -4-Ethyl-9-(phenylethynyl)-3,4,4a,5,6,10b-hexahydro-2 H -[1,4]oxazino[2,3- f ]quinoline 0.659 2.2-fold 0.580 3.6-fold
  • Example 15 (rac)-cis-9- (Phenylethynyl)-4-propyl-3,4,4a,5,6,10b-hexahydro-2 H -[1,4]oxazino[2,3- f ]quinoline 0.0886 3.2-fold 0.175 5.2-fold
  • Example 16 cis -9-(Phenylethynyl)-4-propyl-3,4,4a,5,6,10b-hexahydro-2 H -[1,4]oxazino[2,3- f ]quinoline 0.047 3.8-fold 0.453 6.0-fold
  • Example 17 cis -9-(
  • Example 49 3-(Phenylethynyl)- N,N -bis(2,2,2-trifluoroethyl)-7,8-dihydro-1,6-naphthyridine-6(5 H )-carboxamide n.d. 1.7-fold 0.0118 2.3-fold
  • Example 50 (3-(Phenylethynyl)-7,8-dihydro-1,6-naphthyridin-6(5 H )-yl)(piperidin-1-yl)methanone 0.843 2.1-fold n.d.
  • Example 67 ( rac )-3'-((3-Fluorophenyl)ethynyl)-3-phenyl-7',8'-dihydro-6' H -spiro[oxazolidine-5,5'-quinolin]-2-one 1.31 2.1-fold 0.0883 1.7-fold
  • Example 71 (6a R ,9a R )-Methyl 3-(phenylethynyl)-6,6a,9,9a-tetrahydro-5 H -pyrrolo[2,3- h ]quinoline-7(8 H )-carboxylate 0.241 2.2-fold 0.0327 1.3-fold
  • Example 72 (6a R ,9a R )-Methyl 3-((3-fluorophenyl)ethynyl)-6,6a,9,9a-tetrahydro-5 H -pyrrolo[2,3- h ]quinoline-7(8 H )-carboxylate
  • Example 73 ( rac )- cis -Methyl 3-((3-fluorophenyl)ethynyl)-5a,6,8,8a-tetrahydropyrrolo[3',4':4 ,5]cyclopenta[1,2- b ]pyridine-7(5 H )-carboxylate 0.546 2.7-fold 0.219 2.7-fold
  • Example 74 ( rac )-3-Cyclopropyl-3'-(phenylethynyl)-7',8'-dihydro-6' H -spiro[oxazolidine-5,5'-quinolin]-2-one n.d.
  • Example 77 Ethyl 2-oxo-2-(3-(phenylethynyl)-7,8-dihydro-1,6-naphthyridin-6(5 H )-yl)acetate 0.0254 2.8-fold 0.0221 2.8-fold
  • Example 78 6-((4-Methylpiperazin-1-yl)sulfonyl)-3-(phenylethynyl)-5,6,7,8-tetrahydro-1,6-naphthyridine 2.02 1.7-fold 2.05 n.d.
  • Example 79 ( rac )-Methyl 3-(phenylethynyl)-5a,6,8,8a-tetrahydropyrrolo[3',4':4 ,5]cyclopenta[1,2-b]pyridine-7(5 H )-carboxylate 0.0647 2.6-fold 0.167 4.1-fold
  • Example 82 ( rac )-3'-(Phenylethynyl)-3-propyl-7',8'-dihydro-6' H -spiro[oxazolidine-5,5'-quinolin]-2-one 0.727 1.9-fold 0.233 1.6-fold Table A2 Compound Chemical Name hIC 50 [ ⁇ M] rIC 50 [ ⁇ M]
  • Example 3 ( rac )-6-((5-Methoxy-5,6,7,8-tetrahydroquinolin-3-yl)ethynyl)pyridin-2-amine 4.23 n.d.
  • Example 4 ( rac )-5-Methoxy-7,7-dimethyl-3-(phenylethynyl)-5,6,7,8-tetrahydroquinoline 0.341 n.d.
  • Example 5 ( rac )-6-((5-Methoxy-7,7-dimethyl-5,6,7,8-tetrahydroquinolin-3-yl)ethynyl)pyridin-2-amine 0.0667 0.0457
  • Example 6 ( rac )-3-(Imidazo[1,2- a ]pyridin-2-ylethynyl)-5-methoxy-7,7-dimethyl-5,6,7,8-tetrahydroquinoline 0.695 n.d.
  • Example 7 ( rac )-6-((4-Methoxy-2,2-dimethyl-3,4-dihydro-2 H -pyrano[2,3- b ]pyridin-6-yl)ethynyl)pyridin-2-amine 0.203 n.d.
  • Example 8 ( rac )-6-(Imidazo[1,2- a ]pyridin-2-ylethynyl)-4-methoxy-2,2-dimethyl-3,4-dihydro-2 H -pyrano[2,3-b]pyridine 0.225 n.d.
  • Example 35 1-(3-((6-Aminopyridin-2-yl)ethynyl)-7,8-dihydro-1,6-naphthyridin-6(5 H )-yl)-2,2-dimethylpropan-1-one 0.617 n.d.
  • Example 44 N,N -Dimethyl-3-(phenylethynyl)-7,8-dihydro-1,6-naphthyridine-6(5 H )-carboxamide 0.247 n.d.
  • Example 45 3-((3-Fluorophenyl)ethynyl)- N,N -dimethyl-7,8-dihydro-1,6-naphthyridine-6(5 H )-carboxamide 0.114 0.0559
  • Example 46 3-((3-Cyanophenyl)ethynyl)- N,N -dimethyl-7,8-dihydro-1,6-naphthyridine6(5 H )-carboxamide 0.0508 0.0208
  • Example 47 3-((6-Aminopyridin-2-yl)ethynyl)- N,N -dimethyl-7,8-dihydro-1,6-naphthyridine-6(5 H )-carboxamide 0.261 n.d.
  • Example 51 3-((6-(Piperidine-1-carbonyl)-5,6,7,8-tetrahydro-1,6-naphthyridin-3-yl)ethynyl)benzonitrile 0.740 2.33
  • Example 57 ( rac )-8-Methyl-3-(phenylethynyl)-9,10,10a,11-tetrahydro-5 H -pyrimido[1,6- g ][1,6]naphthyridin-7(8 H )-one 0.190 n.d.
  • Example 61 ( rac )- cis -Methyl 3-((3-fluorophenyl)ethynyl)-7,8,9,9a-tetrahydro-5 H -cyclopenta[ h ][1,6]naphthyridine-6(6a H )-carboxylate 0.132 n.d.
  • Example 62 ( rac )- cis -Methyl 3-(phenylethynyl)-6a,7,8,9,10,10a-hexahydrobenzo[ h ][1,6]naphthyridine-6(5 H )-carboxylate 1.40 n.d.
  • Example 63 ( rac )- cis -Methyl 3-((3-fluorophenyl)ethynyl)-6a,7,8,9,10,10a-hexahydrobenzo[ h ][1,6]naphthyridine-6(5 H )-carboxylate 1.32 n.d.
  • Example 68 3-( m -Tolylethynyl)-7,8-dihydro-5 H -thiopyrano[4,3- b ]pyridine 6,6-dioxide 0.0755 n.d.
  • Example 33 2-Methyl-1-(3-(phenylethynyl)-7,8-dihydro-1,6-naphthyridin-6(5 H )-yl)propan-1-one 1.4-fold 1.3-fold 0.395
  • Example 40 Ethyl 3-(phenylethynyl)-7, 8-dihydro-1,6-naphthyridine-6(5 H )-carboxylate 1.3-fold 1.6-fold 0.0565
  • Example 64 ( rac )-3-Propyl-3'-( m -tolylethynyl)-7',8'-dihydro-6' H -spiro[oxazolidine-5,5'-quinolin]-2-one 1.2-fold 0.9-fold 0.399
  • Example 66 ( rac )-3'-((3-Fluorophenyl)ethynyl)-3-propyl-7',8'-di
  • Example 80 (rac )-cis-Methyl 7-(phenylethynyl)-2,3,3a,4,5,9b-hexahydro-1 H -pyrrolo[3,2- h ]quinoline-1-carboxylate 1.5-fold 1.8-fold n.d. (r EC 50 : 0.0355)
  • Example 81 6-(Isopropylsulfonyl)-3-(phenylethynyl)-5,6,7,8-tetrahydro-1,6-naphthyridine 1.5-fold 1.5-fold n.d.
  • the present invention provides novel and valuable applications and uses of the compounds of the present invention, which compounds comprise the active principle according to the present invention, as well as novel pharmaceutical compositions thereof and methods of preparation thereof and of treating therewith.
  • the instant compounds of Formula I represent a novel class of mGluR5 modulators. In view of their potency, they will be useful therapeutics in a wide range of disorders, in particular CNS disorders, which involve excessive glutamate induced excitation.
  • Neuroprotection as well as cognitive enhancement may also be achieved by administration of the instant compounds in combination with a NMDA receptor antagonist like Memantine.
  • the method-of-treating a living animal body with a compound of the invention, for the inhibition of progression or alleviation of the selected ailment therein, is as previously stated by any normally-accepted pharmaceutical route, employing the selected dosage which is effective in the alleviation of the particular ailment desired to be alleviated.
  • Use of the compounds of the present invention in the manufacture of a medicament for the treatment of a living animal for inhibition of progression or alleviation of selected ailments or conditions, particularly ailments or conditions susceptible to treatment with a Group I mGluR modulator is carried out in the usual manner comprising the step of admixing an effective amount of a compound of the invention with a pharmaceutically-acceptable diluent, excipient, or carrier, and the method-of-treating, pharmaceutical compositions, and use of a compound of the present invention in the manufacture of a medicament.
  • compositions prepared by admixing the active ingredient with a suitable pharmaceutically-acceptable excipient, diluent, or carrier include tablets, capsules, solutions for injection, liquid oral formulations, aerosol formulations, TDS formulations, and nanoparticle formulations, thus to produce medicaments for oral, injectable, or dermal use, also in accord with the foregoing.

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP12163604.7A 2012-04-10 2012-04-10 Dérivés hétérocycliques comme modulateurs de récepteurs du glutamate métabotropique Ceased EP2650284A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP12163604.7A EP2650284A1 (fr) 2012-04-10 2012-04-10 Dérivés hétérocycliques comme modulateurs de récepteurs du glutamate métabotropique

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12163604.7A EP2650284A1 (fr) 2012-04-10 2012-04-10 Dérivés hétérocycliques comme modulateurs de récepteurs du glutamate métabotropique

Publications (1)

Publication Number Publication Date
EP2650284A1 true EP2650284A1 (fr) 2013-10-16

Family

ID=45937078

Family Applications (1)

Application Number Title Priority Date Filing Date
EP12163604.7A Ceased EP2650284A1 (fr) 2012-04-10 2012-04-10 Dérivés hétérocycliques comme modulateurs de récepteurs du glutamate métabotropique

Country Status (1)

Country Link
EP (1) EP2650284A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016029454A1 (fr) * 2014-08-29 2016-03-03 Merck Sharp & Dohme Corp. Dérivés de tétrahydronaphtyridine comme modulateurs allostériques négatifs de mglur2, compositions et leur utilisation
WO2017036978A1 (fr) * 2015-08-28 2017-03-09 Abbvie Inc. Composés hétérocycliques condensés à titre de modulateurs de s1p
CN107021965A (zh) * 2017-05-16 2017-08-08 无锡捷化医药科技有限公司 一种合成5,6,7,8‑四氢‑1,6‑萘啶‑2胺的方法

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4122193A (en) 1972-04-20 1978-10-24 Merz & Co. Drugs or medicines for influencing the central nervous system
US4273774A (en) 1978-12-27 1981-06-16 Merz & Co. Central nervous system compositions and method
US5061703A (en) 1989-04-14 1991-10-29 Merz + Co. Gmbh & Co. Adamantane derivatives in the prevention and treatment of cerebral ischemia
WO2007023242A1 (fr) * 2005-08-24 2007-03-01 Merz Pharma Gmbh & Co. Kgaa Tétrahydroquinolinones et leur usage en tant que modulateurs des récepteurs de glutamate métabotropiques
WO2008071646A1 (fr) * 2006-12-11 2008-06-19 Boehringer Ingelheim International Gmbh Nouveaux dérivés pyridazines à activité antagoniste du récepteur mch et médicaments comprenant ces composés
WO2010018154A1 (fr) 2008-08-12 2010-02-18 Novartis Ag Procédés de préparation d'ester méthylique d'acide 4-oxo-octahydro-indole-1-carbocylique et de ses dérivés
WO2010030954A1 (fr) * 2008-09-11 2010-03-18 Amgen Inc. Composés cycliques spiro-tétracycliques utiles en tant que modulateurs de la bêta-sécrétase et leurs procédés d'utilisation
WO2011115928A1 (fr) * 2010-03-15 2011-09-22 Amgen Inc. Composés spiro de l'amino-dihydrooxazine et de l'amino-dihydrothiazine en tant que modulateurs de la béta-sécrétase et utilisation médicale associée
WO2011115938A1 (fr) * 2010-03-15 2011-09-22 Amgen Inc. Composés spiro tétracycliques en tant que modulateurs de la béta-sécrétase
WO2012052451A1 (fr) * 2010-10-18 2012-04-26 Merz Pharma Gmbh & Co. Kgaa Modulateurs des récepteurs métabotropes au glutamate

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4122193A (en) 1972-04-20 1978-10-24 Merz & Co. Drugs or medicines for influencing the central nervous system
US4273774A (en) 1978-12-27 1981-06-16 Merz & Co. Central nervous system compositions and method
US5061703A (en) 1989-04-14 1991-10-29 Merz + Co. Gmbh & Co. Adamantane derivatives in the prevention and treatment of cerebral ischemia
WO2007023242A1 (fr) * 2005-08-24 2007-03-01 Merz Pharma Gmbh & Co. Kgaa Tétrahydroquinolinones et leur usage en tant que modulateurs des récepteurs de glutamate métabotropiques
WO2008071646A1 (fr) * 2006-12-11 2008-06-19 Boehringer Ingelheim International Gmbh Nouveaux dérivés pyridazines à activité antagoniste du récepteur mch et médicaments comprenant ces composés
WO2010018154A1 (fr) 2008-08-12 2010-02-18 Novartis Ag Procédés de préparation d'ester méthylique d'acide 4-oxo-octahydro-indole-1-carbocylique et de ses dérivés
WO2010030954A1 (fr) * 2008-09-11 2010-03-18 Amgen Inc. Composés cycliques spiro-tétracycliques utiles en tant que modulateurs de la bêta-sécrétase et leurs procédés d'utilisation
WO2011115928A1 (fr) * 2010-03-15 2011-09-22 Amgen Inc. Composés spiro de l'amino-dihydrooxazine et de l'amino-dihydrothiazine en tant que modulateurs de la béta-sécrétase et utilisation médicale associée
WO2011115938A1 (fr) * 2010-03-15 2011-09-22 Amgen Inc. Composés spiro tétracycliques en tant que modulateurs de la béta-sécrétase
WO2012052451A1 (fr) * 2010-10-18 2012-04-26 Merz Pharma Gmbh & Co. Kgaa Modulateurs des récepteurs métabotropes au glutamate

Non-Patent Citations (26)

* Cited by examiner, † Cited by third party
Title
"Remington: The Science and Practice of Pharmacy"
A.R. GENNARO: "Remington: The Science and Practice of Pharmacy"
ABDEL-MAGID ET AL., J. ORG. CHEM., vol. 61, 1996, pages 3849 - 3862
BOCKAERT ET AL., THE EMBO JOURNAL, vol. 18, 1999, pages 1723 - 1729
BOOHER; SENSENBRENNER, NEUROBIOLOGY, vol. 2, no. 3, 1972, pages 97 - 105
DANYSZ ET AL., CURR. PHARM. DES., vol. 8, 2002, pages 835 - 43
FOSTER; WONG, BR. J. PHARMACOL., vol. 91, 1987, pages 403 - 409
GORTELMEYER ET AL., ARZNEIM-FORSCH/DRUG RES., vol. 42, 1992, pages 904 - 913
JIRGENSONS, EUR. J. MED. CHEM., vol. 35, 2000, pages 555 - 565
KAMOGAWA ET AL., HETEROCYCLES, vol. 82, 2010, pages 325 - 332
KD, CHENG; PRUSSOFF, BIOCHEM. PHARMACOL., vol. 22, 1973, pages 3099 - 3108
LOWRY ET AL., J. BIOL. CHEM., vol. 193, 1951, pages 256 - 275
MAKSIMS VANEJEVS ET AL: "Positive and negative modulation of group I metabotropic glutamate receptors", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 51, no. 3, 14 February 2008 (2008-02-14), pages 634 - 647, XP002626404, ISSN: 0022-2623, [retrieved on 20080104], DOI: 10.1021/JM0611298 *
MILLER ET AL., BRAIN RES., vol. 618, no. 1, 1993, pages 175 - 8
NOZULAK ET AL., J. MED. CHEM., vol. 35, 1992, pages 480 - 489
PARSONS ET AL., J. PHARMACOL. EXP. THER., vol. 283, no. 3, 1997, pages 1264 - 1275
RODRIGUEZ ET AL., MOLECULAR PHARMACOLOGY, vol. 68, 2005, pages 1793 - 1802
ROGAWSKI, AMINO ACIDS, vol. 19, 2000, pages 133 - 49
SEIFERT ET AL., NAUNYN SCHMIEDEBERGS ARCH PHARMACOL., vol. 366, 2002, pages 381 - 416
STELLA V. ET AL.: "Prodrugs: Challenges and Rewards", 2007, AAPS PRESS/SPRINGER, NEW YORK
SYNTHESIS 1995, 1995, pages 592 - 604
VANEJEVS ET AL., J. MED. CHEM., vol. 51, 2008, pages 634 - 647
WINBLAD ET AL., INT. J. GERIAT. PSYCHIATRY, vol. 14, 1999, pages 135 - 146
ZIEMINSKA ET AL., ACTA NEUROBIOL. EXP., vol. 66, 2006, pages 301 - 309
ZIEMINSKA ET AL., NEUROCHEMISTRY INTERNATIONAL, vol. 43, 2003, pages 481 - 492
ZIEMINSKA ET AL., NEUROCHEMISTRY INTERNATIONAL, vol. 48, 2006, pages 491 - 497

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016029454A1 (fr) * 2014-08-29 2016-03-03 Merck Sharp & Dohme Corp. Dérivés de tétrahydronaphtyridine comme modulateurs allostériques négatifs de mglur2, compositions et leur utilisation
US10072003B2 (en) 2014-08-29 2018-09-11 Merck Sharp & Dohme Corp. Tetrahydronaphthyridine derivatives as mGluR2-negative allosteric modulators, compositions, and their use
WO2017036978A1 (fr) * 2015-08-28 2017-03-09 Abbvie Inc. Composés hétérocycliques condensés à titre de modulateurs de s1p
CN108368107A (zh) * 2015-08-28 2018-08-03 艾伯维公司 作为s1p调节剂的稠合杂环化合物
US10556907B2 (en) 2015-08-28 2020-02-11 AbbVie Deutschland GmbH & Co. KG Fused heterocyclic compounds as S1P modulators
CN107021965A (zh) * 2017-05-16 2017-08-08 无锡捷化医药科技有限公司 一种合成5,6,7,8‑四氢‑1,6‑萘啶‑2胺的方法
CN107021965B (zh) * 2017-05-16 2019-08-13 无锡捷化医药科技有限公司 一种合成5,6,7,8-四氢-1,6-萘啶-2胺的方法

Similar Documents

Publication Publication Date Title
EP2054421B1 (fr) Pyrazolopyrimidines, procédé permettant de les préparer et de les utiliser en tant que médicaments
US20120178742A1 (en) Metabotropic glutamate receptor modulators
WO2009095253A1 (fr) 6-halo-pyrazolo[1,5-a]pyridines, leur méthode de préparation et leur utilisation comme modulateurs des récepteurs métabotropiques du glutamate (mglur)
EP2247590A1 (fr) Pyrazolopyrimidines, leur méthode de préparation et leur utilisation comme médicaments
JP5584352B2 (ja) β−セクレターゼ調節剤としてのアミノ−ジヒドロオキサジン系およびアミノ−ジヒドロチアジン系スピロ化合物ならびにそれらの医学的用途
WO2012085167A1 (fr) Modulateurs des récepteurs glutamatergiques métabotropes
KR20160065950A (ko) 열 충격 전사인자 1의 억제제로서 융합된 1,4-디히드로디옥신 유도체
WO2012052451A1 (fr) Modulateurs des récepteurs métabotropes au glutamate
WO2012172093A1 (fr) Dérivé de dihydroindolizine à titre de modulateurs des récepteurs métabotropes de glutamate
WO2012085166A1 (fr) Modulateurs des récepteurs glutamatergiques métabotropes
EP2650284A1 (fr) Dérivés hétérocycliques comme modulateurs de récepteurs du glutamate métabotropique
ES2356576T3 (es) Pirazolopirimidinas, un proceso para su preparación y su uso como medicamento.
AU2021356875A1 (en) HETEROCYCLIC SUBSTITUTED FUSED γ-CARBOLINE DERIVATIVE, PREPARATION METHOD THEREFOR, INTERMEDIATE THEREOF AND USE THEREOF
CA3238577A1 (fr) Inhibiteurs de pad4 et leur utilisation
KR20160003752A (ko) 피라지노[1,2-a]인돌 화합물들, 그들의 제조 및 의약에서의 이용
WO2012152854A1 (fr) Modulateurs de récepteur de glutamate métabotropique
TW201305110A (zh) 促代謝性麩胺酸受體調節劑
NZ716609B2 (en) Fused piperidine amides as modulators of ion channels

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20140310